Loading...

David R Gandara

Title(s)Professor, Hematology and Oncology
SchoolUniversity of California, Davis
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel S, Redman MW, Gandara DR, Kelly K. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J Clin Oncol. 2019 Aug 06; JCO1900269. PMID: 31386610.
      View in: PubMed
    2. Burd A, Schilsky RL, Byrd JC, Levine RL, Papadimitrakopoulou VA, Herbst RS, Redman MW, Druker BJ, Gandara DR. Challenges and approaches to implementing master/basket trials in oncology. Blood Adv. 2019 Jul 23; 3(14):2237-2243. PMID: 31337605.
      View in: PubMed
    3. Edelman MJ, Redman MW, Albain KS, McGary EC, Rafique NM, Petro D, Waqar SN, Minichiello K, Miao J, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS. Brief Report: SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-study). J Thorac Oncol. 2019 Jul 11. PMID: 31302234.
      View in: PubMed
    4. Schulz C, Gandara D, Berardo CG, Rosenthal R, Foo J, Morel C, Ballinger M, Watkins C, Chu P. Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies. Clin Lung Cancer. 2019 Jun 19. PMID: 31375454.
      View in: PubMed
    5. Aggarwal C, Redman MW, Lara PN, Borghaei H, Hoffman P, Bradley JD, Newman AJ, Feldman MJ, Minichiello K, Miao J, Mack PC, Papadimitrakopoulou VA, Herbst RS, Kelly K, Gandara DR. Brief Report: SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously-treated Patients with Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). J Thorac Oncol. 2019 Jun 10. PMID: 31195180.
      View in: PubMed
    6. Xie H, Yin J, Shah MH, Menefee ME, Bible KC, Reidy-Lagunes D, Kane MA, Quinn DI, Gandara DR, Erlichman C, Adjei AA. A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma. Invest New Drugs. 2019 Jun 06. PMID: 31172443.
      View in: PubMed
    7. Langer CJ, Redman MW, Wade JL, Aggarwal C, Bradley JD, Crawford J, Stella PJ, Knapp MH, Miao J, Minichiello K, Herbst RS, Kelly K, Gandara DR, Papadimitrakopoulou VA. Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). J Thorac Oncol. 2019 May 31. PMID: 31158500.
      View in: PubMed
    8. Pennell NA, Arcila ME, Gandara DR, West H. Biomarker Testing for Patients With Advanced Non-Small Cell Lung Cancer: Real-World Issues and Tough Choices. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:531-542. PMID: 31099633.
      View in: PubMed
    9. Reckamp KL, Frankel PH, Ruel N, Mack PC, Gitlitz BJ, Li T, Koczywas M, Gadgeel SM, Cristea MC, Belani CP, Newman EM, Gandara DR, Lara PN. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303). Front Oncol. 2019; 9:132. PMID: 30915273.
      View in: PubMed
    10. Semrad TJ, Groshen S, Luo C, Pal S, Vaishampayan U, Joshi M, Quinn DI, Mack PC, Gandara DR, Lara PN. Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib - Results of NCI/CTEP Protocol 9048. Kidney Cancer. 2019 Feb 05; 3(1):51-61. PMID: 30854497.
      View in: PubMed
    11. Narayanan A, Knollmann FD, Walby JAS, Lim S, Gandara DR, Riess JW. EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade. Clin Lung Cancer. 2018 Dec 27. PMID: 30679078.
      View in: PubMed
    12. von Pawel J, Bordoni R, Satouchi M, Fehrenbacher L, Cobo M, Han JY, Hida T, Moro-Sibilot D, Conkling P, Gandara DR, Rittmeyer A, Gandhi M, Yu W, Matheny C, Patel H, Sandler A, Ballinger M, Kowanetz M, Park K. Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. Eur J Cancer. 2019 Jan; 107:124-132. PMID: 30562710.
      View in: PubMed
    13. Carbone M, Amelio I, Affar EB, Brugarolas J, Cannon-Albright LA, Cantley LC, Cavenee WK, Chen Z, Croce CM, Andrea A, Gandara D, Giorgi C, Jia W, Lan Q, Mak TW, Manley JL, Mikoshiba K, Onuchic JN, Pass HI, Pinton P, Prives C, Rothman N, Sebti SM, Turkson J, Wu X, Yang H, Yu H, Melino G. Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine. Cell Death Differ. 2018 Nov; 25(11):1885-1904. PMID: 30323273.
      View in: PubMed
    14. Yu H, Chen Z, Ballman KV, Watson MA, Govindan R, Lanc I, Beer DG, Bueno R, Chirieac LR, Chui MH, Chen G, Franklin WA, Gandara DR, Genova C, Brovsky KA, Joshi MM, Merrick DT, Richards WG, Rivard CJ, Harpole DH, Tsao MS, van Bokhoven A, Shepherd FA, Hirsch FR. Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. J Thorac Oncol. 2019 Jan; 14(1):25-36. PMID: 30253973.
      View in: PubMed
    15. Gandara DR, von Pawel J, Mazieres J, Sullivan R, Helland Å, Han JY, Ponce Aix S, Rittmeyer A, Barlesi F, Kubo T, Park K, Goldschmidt J, Gandhi M, Yun C, Yu W, Matheny C, He P, Sandler A, Ballinger M, Fehrenbacher L. Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study. J Thorac Oncol. 2018 Dec; 13(12):1906-1918. PMID: 30217492.
      View in: PubMed
    16. Gandara DR, Riess JW, Lara PN. In Search of an Oncogene Driver for Squamous Lung Cancer. JAMA Oncol. 2018 Sep 01; 4(9):1197-1198. PMID: 29902311.
      View in: PubMed
    17. Liu SV, Groshen SG, Kelly K, Reckamp KL, Belani C, Synold TW, Goldkorn A, Gitlitz BJ, Cristea MC, Gong IY, Semrad TJ, Xu Y, Xu T, Koczywas M, Gandara DR, Newman EM. A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2018 Oct; 82(4):723-732. PMID: 30128950.
      View in: PubMed
    18. Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, Rittmeyer A, Fehrenbacher L, Otto G, Malboeuf C, Lieber DS, Lipson D, Silterra J, Amler L, Riehl T, Cummings CA, Hegde PS, Sandler A, Ballinger M, Fabrizio D, Mok T, Shames DS. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018 09; 24(9):1441-1448. PMID: 30082870.
      View in: PubMed
    19. Riess JW, Gandara DR, Frampton GM, Madison R, Peled N, Bufill JA, Dy GK, Ou SI, Stephens PJ, McPherson JD, Lara PN, Burich RA, Ross JS, Miller VA, Ali SM, Mack PC, Schrock AB. Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. J Thorac Oncol. 2018 Oct; 13(10):1560-1568. PMID: 29981927.
      View in: PubMed
    20. Cheng TD, Darke AK, Redman MW, Zirpoli GR, Davis W, Payne Ondracek R, Bshara W, Omilian AR, Kratzke R, Reid ME, Molina JR, Kolesar JM, Chen Y, MacRae RM, Moon J, Mack P, Gandara DR, Kelly K, Santella RM, Albain KS, Ambrosone CB. Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424). J Natl Cancer Inst. 2018 Jul 01; 110(7):734-742. PMID: 29346580.
      View in: PubMed
    21. Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DSW, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. J Thorac Oncol. 2018 Sep; 13(9):1248-1268. PMID: 29885479.
      View in: PubMed
    22. Chu LL, Knebel RJ, Shay AD, Santos J, Badawi RD, Gandara DR, Knollmann FD. CT perfusion imaging of lung cancer: benefit of motion correction for blood flow estimates. Eur Radiol. 2018 Dec; 28(12):5069-5075. PMID: 29869174.
      View in: PubMed
    23. Zill OA, Banks KC, Fairclough SR, Mortimer SA, Vowles JV, Mokhtari R, Gandara DR, Mack PC, Odegaard JI, Nagy RJ, Baca AM, Eltoukhy H, Chudova DI, Lanman RB, Talasaz A. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. Clin Cancer Res. 2018 Aug 01; 24(15):3528-3538. PMID: 29776953.
      View in: PubMed
    24. Fehrenbacher L, von Pawel J, Park K, Rittmeyer A, Gandara DR, Ponce Aix S, Han JY, Gadgeel SM, Hida T, Cortinovis DL, Cobo M, Kowalski DM, De Marinis F, Gandhi M, Danner B, Matheny C, Kowanetz M, He P, Felizzi F, Patel H, Sandler A, Ballinger M, Barlesi F. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 08; 13(8):1156-1170. PMID: 29777823.
      View in: PubMed
    25. Claret L, Jin JY, Ferté C, Winter H, Girish S, Stroh M, He P, Ballinger M, Sandler A, Joshi A, Rittmeyer A, Gandara D, Soria JC, Bruno R. A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics. Clin Cancer Res. 2018 Jul 15; 24(14):3292-3298. PMID: 29685883.
      View in: PubMed
    26. Hirsch FR, Kerr KM, Bunn PA, Kim ES, Obasaju C, Pérol M, Bonomi P, Bradley JD, Gandara D, Jett JR, Langer CJ, Natale RB, Novello S, Paz-Ares L, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Stinchcombe TE, Vansteenkiste JF, Wakelee H, Thatcher N. Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. Clin Lung Cancer. 2018 07; 19(4):331-339. PMID: 29773328.
      View in: PubMed
    27. El-Khoueiry AB, O'Donnell R, Semrad TJ, Mack P, Blanchard S, Bahary N, Jiang Y, Yen Y, Wright J, Chen H, Lenz HJ, Gandara DR. A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2018 May; 81(5):957-963. PMID: 29520435.
      View in: PubMed
    28. Floc'h N, Martin MJ, Riess JW, Orme JP, Staniszewska AD, Ménard L, Cuomo ME, O'Neill DJ, Ward RA, Finlay MRV, McKerrecher D, Cheng M, Vang DP, Burich RA, Keck JG, Gandara DR, Mack PC, Cross DAE. Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol Cancer Ther. 2018 05; 17(5):885-896. PMID: 29483211.
      View in: PubMed
    29. Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn PA, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Wakelee H, Thatcher N. Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. J Thorac Oncol. 2018 02; 13(2):165-183. PMID: 29175116.
      View in: PubMed
    30. Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol. 2018 01; 19(1):101-114. PMID: 29169877.
      View in: PubMed
    31. Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Aisner SC, Rothman JM, Patel JD, Sborov MD, McDermott SR, Perez-Soler R, Traynor AM, Butts C, Evans T, Shafqat A, Chapman AE, Kasbari SS, Horn L, Ramalingam SS, Schiller JH. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2017 12; 18(12):1610-1623. PMID: 29129443.
      View in: PubMed
    32. Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017 Dec; 49(12):1693-1704. PMID: 29106415.
      View in: PubMed
    33. Lara JD, Brunson A, Riess JW, Kelly K, Lara PN, Gandara DR. Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry. Lung Cancer. 2017 10; 112:165-168. PMID: 29191590.
      View in: PubMed
    34. Hortobagyi GN, Pyle D, Cazap EL, El Saghir NS, Shulman LN, Lyman GH, Schnipper LE, Adebamowo CA, Gandara DR, Vose J, Wong SL, Yu P. American Society of Clinical Oncology's Global Oncology Leadership Task Force: Findings and Actions. J Glob Oncol. 2018 Sep; 4:1-8. PMID: 30241187.
      View in: PubMed
    35. West HL, Moon J, Wozniak AJ, Mack P, Hirsch FR, Bury MJ, Kwong M, Nguyen DD, Moore DF, Miao J, Redman M, Kelly K, Gandara DR. Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer. 2018 01; 19(1):84-92. PMID: 28801183.
      View in: PubMed
    36. Van Der Steen N, Mentens Y, Ramael M, Leon LG, Germonpré P, Ferri J, Gandara DR, Giovannetti E, Peters GJ, Pauwels P, Rolfo C. Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC. Clin Lung Cancer. 2018 01; 19(1):35-41. PMID: 28757336.
      View in: PubMed
    37. Melosky B, Popat S, Gandara DR. An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach. Clin Lung Cancer. 2018 01; 19(1):42-50. PMID: 28668205.
      View in: PubMed
    38. Tsao AS, Moon J, Wistuba II, Vogelzang NJ, Kalemkerian GP, Redman MW, Gandara DR, Kelly K. Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J Thorac Oncol. 2017 08; 12(8):1299-1308. PMID: 28599887.
      View in: PubMed
    39. Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR. Scientific Advances in Thoracic Oncology 2016. J Thorac Oncol. 2017 08; 12(8):1183-1209. PMID: 28579481.
      View in: PubMed
    40. Somlo G, Frankel PH, Arun BK, Ma CX, Garcia AA, Cigler T, Cream LV, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan TJ, Vahdat LT, Goetz MP, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow KV, Chen AP, Ruel C, Newman EM, Gandara DR, Weitzel JN. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res. 2017 Aug 01; 23(15):4066-4076. PMID: 28356425.
      View in: PubMed
    41. Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol. 2017 May 01; 35(13):1403-1410. PMID: 28447912.
      View in: PubMed
    42. Peled N, Roisman LC, Miron B, Pfeffer R, Lanman RB, Ilouze M, Dvir A, Soussan-Gutman L, Barlesi F, Tarcic G, Edelheit O, Gandara D, Elkabetz Y. Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-Mutated Lung Cancer. J Thorac Oncol. 2017 07; 12(7):e81-e84. PMID: 28286242.
      View in: PubMed
    43. Fahrmann JF, Grapov DD, Wanichthanarak K, DeFelice BC, Salemi MR, Rom WN, Gandara DR, Phinney BS, Fiehn O, Pass H, Miyamoto S. Integrated Metabolomics and Proteomics Highlight Altered Nicotinamide- and Polyamine Pathways in Lung Adenocarcinoma. Carcinogenesis. 2017 Jan 03. PMID: 28049629.
      View in: PubMed
    44. Semrad TJ, Kim EJ, Tanaka MS, Sands J, Roberts C, Burich RA, Li Y, Gandara DR, Lara P, Mack PC. Phase II Study of Dovitinib in Patients Progressing on Anti-Vascular Endothelial Growth Factor Therapy. Cancer Treat Res Commun. 2017; 10:21-26. PMID: 28736761.
      View in: PubMed
    45. Gandara DR, Riess JW, Kelly K, Li T, Mack PC, Lara PN. Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):1-4. PMID: 28082049.
      View in: PubMed
    46. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017 01 21; 389(10066):255-265. PMID: 27979383.
      View in: PubMed
    47. Lara MS, Holland WS, Chinn D, Burich RA, Lara PN, Gandara DR, Kelly K, Mack PC. Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 May; 18(3):281-285. PMID: 28038979.
      View in: PubMed
    48. Gandara DR, Leighl N, Delord JP, Barlesi F, Bennouna J, Zalcman G, Infante JR, Reckamp KL, Kelly K, Shepherd FA, Mazieres J, Janku F, Gardner OS, Mookerjee B, Wu Y, Cox DS, Schramek D, Peddareddigari V, Liu Y, D'Amelio AM, Blumenschein G. A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 03; 12(3):556-566. PMID: 27876675.
      View in: PubMed
    49. Cho H, Matsumoto S, Fujita Y, Kuroda A, Menju T, Sonobe M, Kondo N, Torii I, Nakano T, Lara PN, Gandara DR, Date H, Hasegawa S. Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma. J Thorac Oncol. 2017 03; 12(3):477-490. PMID: 27867002.
      View in: PubMed
    50. Riess JW, Lara PN, Gandara DR. Theory Meets Practice for Immune Checkpoint Blockade in Small-Cell Lung Cancer. J Clin Oncol. 2016 11 01; 34(31):3717-3718. PMID: 27601544.
      View in: PubMed
    51. Li T, Piperdi B, Walsh WV, Kim M, Beckett LA, Gucalp R, Haigentz M, Bathini VG, Wen H, Zhou K, Pasquinelli PB, Gajavelli S, Sreedhara M, Xie X, Lara PN, Gandara DR, Perez-Soler R. Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):60-67. PMID: 27919627.
      View in: PubMed
    52. Fahrmann JF, Grapov D, Phinney BS, Stroble C, DeFelice BC, Rom W, Gandara DR, Zhang Y, Fiehn O, Pass H, Miyamoto S. Proteomic profiling of lung adenocarcinoma indicates heightened DNA repair, antioxidant mechanisms and identifies LASP1 as a potential negative predictor of survival. Clin Proteomics. 2016; 13:31. PMID: 27799870.
      View in: PubMed
    53. Pang HH, Wang X, Stinchcombe TE, Wong ML, Cheng P, Ganti AK, Sargent DJ, Zhang Y, Hu C, Mandrekar SJ, Redman MW, Manola JB, Schilsky RL, Cohen HJ, Bradley JD, Adjei AA, Gandara D, Ramalingam SS, Vokes EE. Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. J Clin Oncol. 2016 11 20; 34(33):3992-3999. PMID: 27646951.
      View in: PubMed
    54. Kirschbaum MH, Frankel P, Synold TW, Zain J, Claxton D, Tuscano J, Newman EM, Gandara DR, Lara PN. A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium Study. Br J Haematol. 2018 02; 180(3):445-448. PMID: 27650362.
      View in: PubMed
    55. Langer CJ, Obasaju C, Bunn P, Bonomi P, Gandara D, Hirsch FR, Kim ES, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Socinski MA, Spigel DR, Wakelee H, Mayo C, Thatcher N. Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. J Thorac Oncol. 2016 12; 11(12):2066-2081. PMID: 27575423.
      View in: PubMed
    56. Salahudeen AA, Patel MI, Baas P, Curran WJ, Bradley JD, Gandara DR, Goss GD, Mok TS, Ramalingam SS, Vokes EE, Malik SM, Wakelee HA. Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe. Clin Lung Cancer. 2017 01; 18(1):5-12. PMID: 27473736.
      View in: PubMed
    57. Socinski MA, Obasaju C, Gandara D, Hirsch FR, Bonomi P, Bunn P, Kim ES, Langer CJ, Natale RB, Novello S, Paz-Ares L, Pérol M, Reck M, Ramalingam SS, Reynolds CH, Spigel DR, Stinchcombe TE, Wakelee H, Mayo C, Thatcher N. Clinicopathologic Features of Advanced Squamous NSCLC. J Thorac Oncol. 2016 09; 11(9):1411-22. PMID: 27296106.
      View in: PubMed
    58. Raez LE, Santos ES, Rolfo C, Lopes G, Barrios C, Cardona A, Mas LA, Arrieta O, Richardet E, Vallejos S C, Wistuba I, Gandara D, Hirsch FR. Challenges in Facing the Lung Cancer Epidemic and Treating Advanced Disease in Latin America. Clin Lung Cancer. 2017 01; 18(1):e71-e79. PMID: 27426974.
      View in: PubMed
    59. Hirsch FR, Govindan R, Zvirbule Z, Braiteh F, Rittmeyer A, Belda-Iniesta C, Isla D, Cosgriff T, Boyer M, Ueda M, Phan S, Gandara DR. Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 01; 18(1):43-49. PMID: 27461773.
      View in: PubMed
    60. Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA, Mok TS, Hirsch FR. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. J Thorac Oncol. 2016 07; 11(7):946-63. PMID: 27229180.
      View in: PubMed
    61. Tsao AS, Scagliotti GV, Bunn PA, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI. Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016 05; 11(5):613-638. PMID: 27013409.
      View in: PubMed
    62. Kummar S, Wade JL, Oza AM, Sullivan D, Chen AP, Gandara DR, Ji J, Kinders RJ, Wang L, Allen D, Coyne GO, Steinberg SM, Doroshow JH. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Invest New Drugs. 2016 06; 34(3):355-63. PMID: 26996385.
      View in: PubMed
    63. Gandara DR, Redman M, Hirsch FR. Postprogression Prolongation of Survival in EGFR-Mutated Lung Cancer: Reconciling the ASPIRATION and IMPRESS Trials. JAMA Oncol. 2016 Mar; 2(3):300-1. PMID: 26720042.
      View in: PubMed
    64. Bunn PA, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? J Thorac Oncol. 2016 Apr; 11(4):453-74. PMID: 26829312; PMCID: PMC4836290 [Available on 04/01/17].
    65. Ruhaak LR, Stroble C, Dai J, Barnett M, Taguchi A, Goodman GE, Miyamoto S, Gandara D, Feng Z, Lebrilla CB, Hanash S. Serum Glycans as Risk Markers for Non-Small Cell Lung Cancer. Cancer Prev Res (Phila). 2016 Apr; 9(4):317-23. PMID: 26813970; PMCID: PMC4818659 [Available on 04/01/17].
    66. Senan S, Brade A, Wang LH, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, San Antonio B, Chouaki N, Vokes E. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Mar 20; 34(9):953-62. PMID: 26811519.
      View in: PubMed
    67. Carter CA, Rajan A, Keen C, Szabo E, Khozin S, Thomas A, Brzezniak C, Guha U, Doyle LA, Steinberg SM, Xi L, Raffeld M, Tomita Y, Lee MJ, Lee S, Trepel JB, Reckamp KL, Koehler S, Gitlitz B, Salgia R, Gandara D, Vokes E, Giaccone G. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. Ann Oncol. 2016 Apr; 27(4):693-9. PMID: 26802155.
      View in: PubMed
    68. Lara PN, Moon J, Hesketh PJ, Redman MW, Williamson SK, Akerley WL, Hirsch FR, Mack PC, Gandara DR. SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay. J Thorac Oncol. 2016 Mar; 11(3):420-5. PMID: 26725184; PMCID: PMC4775366 [Available on 03/01/17].
    69. Govindan R, Mandrekar SJ, Gerber DE, Oxnard GR, Dahlberg SE, Chaft J, Malik S, Mooney M, Abrams JS, Jänne PA, Gandara DR, Ramalingam SS, Vokes EE. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. Clin Cancer Res. 2015 Dec 15; 21(24):5439-44. PMID: 26672084; PMCID: PMC4683399 [Available on 12/15/16].
    70. Lara PN, Moon J, Redman MW, Semrad TJ, Kelly K, Allen J, Gitlitz B, Mack PC, Gandara DR. Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clin Lung Cancer. 2016 Mar; 17(2):113-8.e1-2. PMID: 26498504.
      View in: PubMed
    71. Chow H, Edelman MJ, Giaccone G, Ramalingam SS, Quill TA, Bowser AD, Mortimer J, Guerra W, Beckett LA, West HL, Lara PN, Gandara DR. Impact of an Interactive On-line Tool on Therapeutic Decision-Making for Patients with Advanced Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015 Oct; 10(10):1421-9. PMID: 25719266.
      View in: PubMed
    72. Morgan RJ, Synold TW, Longmate JA, Quinn DI, Gandara D, Lenz HJ, Ruel C, Xi B, Lewis MD, Colevas AD, Doroshow J, Newman EM. Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial. Cancer Chemother Pharmacol. 2015 Nov; 76(5):897-907. PMID: 26362045; PMCID: PMC4694049 [Available on 11/01/16].
    73. Ferrarotto R, Redman MW, Gandara DR, Herbst RS, Papadimitrakopoulou VA. Lung-MAP--framework, overview, and design principles. Chin Clin Oncol. 2015 Sep; 4(3):36. PMID: 26408303.
      View in: PubMed
    74. Fahrmann JF, Kim K, DeFelice BC, Taylor SL, Gandara DR, Yoneda KY, Cooke DT, Fiehn O, Kelly K, Miyamoto S. Investigation of metabolomic blood biomarkers for detection of adenocarcinoma lung cancer. Cancer Epidemiol Biomarkers Prev. 2015 Nov; 24(11):1716-23. PMID: 26282632; PMCID: PMC4633344 [Available on 11/01/16].
    75. Wikoff WR, Hanash S, DeFelice B, Miyamoto S, Barnett M, Zhao Y, Goodman G, Feng Z, Gandara D, Fiehn O, Taguchi A. Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B. J Clin Oncol. 2015 Nov 20; 33(33):3880-6. PMID: 26282655.
      View in: PubMed
    76. Pan CX, Zhang H, Tepper CG, Lin TY, Davis RR, Keck J, Ghosh PM, Gill P, Airhart S, Bult C, Gandara DR, Liu E, de Vere White RW. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. PLoS One. 2015; 10(8):e0134346. PMID: 26270481; PMCID: PMC4535951.
    77. Afshinnekoo E, Meydan C, Chowdhury S, Jaroudi D, Boyer C, Bernstein N, Maritz JM, Reeves D, Gandara J, Chhangawala S, Ahsanuddin S, Simmons A, Nessel T, Sundaresh B, Pereira E, Jorgensen E, Kolokotronis SO, Kirchberger N, Garcia I, Gandara D, Dhanraj S, Nawrin T, Saletore Y, Alexander N, Vijay P, Hénaff EM, Zumbo P, Walsh M, O'Mullan GD, Tighe S, Dudley JT, Dunaif A, Ennis S, O'Halloran E, Magalhaes TR, Boone B, Jones AL, Muth TR, Paolantonio KS, Alter E, Schadt EE, Garbarino J, Prill RJ, Carlton JM, Levy S, Mason CE. Modern Methods for Delineating Metagenomic Complexity. Cell Syst. 2015 Jul 29; 1(1):6-7. PMID: 27135684.
      View in: PubMed
    78. Gandara DR, Lara PN, Mack PC. Patient-Derived Xenografts for Investigation of Acquired Resistance in Oncogene-Driven Cancers: Building a Better Mousetrap. J Clin Oncol. 2015 Sep 10; 33(26):2839-40. PMID: 26215942.
      View in: PubMed
    79. Hirsch FR, Herbst RS, Gandara DR. EGFR tyrosine kinase inhibitors in squamous cell lung cancer. Lancet Oncol. 2015 Aug; 16(8):872-3. PMID: 26156654.
      View in: PubMed
    80. Foster NR, Renfro LA, Schild SE, Redman MW, Wang XF, Dahlberg SE, Ding K, Bradbury PA, Ramalingam SS, Gandara DR, Shibata T, Saijo N, Vokes EE, Adjei AA, Mandrekar SJ. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. J Thorac Oncol. 2015 Jul; 10(7):1099-106. PMID: 26134227; PMCID: PMC4493926.
    81. Carbone DP, Gandara DR, Antonia SJ, Zielinski C, Paz-Ares L. Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. J Thorac Oncol. 2015 Jul; 10(7):974-84. PMID: 26134219; PMCID: PMC4618296.
    82. Lara PN, Longmate J, Mack PC, Kelly K, Socinski MA, Salgia R, Gitlitz B, Li T, Koczywas M, Reckamp KL, Gandara DR. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. Clin Cancer Res. 2015 Oct 01; 21(19):4321-6. PMID: 26106072; PMCID: PMC4592395 [Available on 10/01/16].
    83. Gandara DR, Hammerman PS, Sos ML, Lara PN, Hirsch FR. Squamous cell lung cancer: from tumor genomics to cancer therapeutics. Clin Cancer Res. 2015 May 15; 21(10):2236-43. PMID: 25979930; PMCID: PMC4862209.
    84. Lara PN, Gandara DR, Redman MW. Reply to "diminishing role of platinum-sensitivity status in patients with small cell lung cancer". J Thorac Oncol. 2015 May; 10(5):e36. PMID: 25898968.
      View in: PubMed
    85. Steuer CE, Papadimitrakopoulou V, Herbst RS, Redman MW, Hirsch FR, Mack PC, Ramalingam SS, Gandara DR. Innovative Clinical Trials: The LUNG-MAP Study. Clin Pharmacol Ther. 2015 May; 97(5):488-91. PMID: 25676724.
      View in: PubMed
    86. Eroglu Z, Tawbi HA, Hu J, Guan M, Frankel PH, Ruel NH, Wilczynski S, Christensen S, Gandara DR, Chow WA. A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas. Br J Cancer. 2015 May 12; 112(10):1644-51. PMID: 25897676.
      View in: PubMed
    87. Miyamoto S, Taylor SL, Barupal DK, Taguchi A, Wohlgemuth G, Wikoff WR, Yoneda KY, Gandara DR, Hanash SM, Kim K, Fiehn O. Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry. Metabolites. 2015 Apr 09; 5(2):192-210. PMID: 25859693; PMCID: PMC4495369.
    88. Heigener DF, Gandara DR, Reck M. Targeting of MEK in lung cancer therapeutics. Lancet Respir Med. 2015 Apr; 3(4):319-27. PMID: 25801412.
      View in: PubMed
    89. Gandara DR, Mack PC, Bult C, Li T, Lara PN, Riess JW, Astrow SH, Gandour-Edwards R, Cooke DT, Yoneda KY, Moore EH, Pan CX, Burich RA, David EA, Keck JG, Airhart S, Goodwin N, de Vere White RW, Liu ET. Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform. Clin Lung Cancer. 2015 May; 16(3):165-72. PMID: 25838158; PMCID: PMC4586173.
    90. Tomlinson BK, Thomson JA, Bomalaski JS, Diaz M, Akande T, Mahaffey N, Li T, Dutia MP, Kelly K, Gong IY, Semrad T, Gandara DR, Pan CX, Lara PN. Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2480-6. PMID: 25739672; PMCID: PMC4452427.
    91. Afshinnekoo E, Meydan C, Chowdhury S, Jaroudi D, Boyer C, Bernstein N, Maritz JM, Reeves D, Gandara J, Chhangawala S, Ahsanuddin S, Simmons A, Nessel T, Sundaresh B, Pereira E, Jorgensen E, Kolokotronis SO, Kirchberger N, Garcia I, Gandara D, Dhanraj S, Nawrin T, Saletore Y, Alexander N, Vijay P, Hénaff EM, Zumbo P, Walsh M, O'Mullan GD, Tighe S, Dudley JT, Dunaif A, Ennis S, O'Halloran E, Magalhaes TR, Boone B, Jones AL, Muth TR, Paolantonio KS, Alter E, Schadt EE, Garbarino J, Prill RJ, Carlton JM, Levy S, Mason CE. Geospatial Resolution of Human and Bacterial Diversity with City-Scale Metagenomics. Cell Syst. 2015 Jul 29; 1(1):72-87. PMID: 26594662.
      View in: PubMed
    92. Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015 Mar; 16(3):257-65. PMID: 25704439.
      View in: PubMed
    93. Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, Li Y, Allen JD, Sigal EV, Wholley D, Sigman CC, Blumenthal GM, Malik S, Kelloff GJ, Abrams JS, Blanke CD, Papadimitrakopoulou VA. Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clin Cancer Res. 2015 Apr 01; 21(7):1514-24. PMID: 25680375; PMCID: PMC4654466.
    94. Wikoff WR, Grapov D, Fahrmann JF, DeFelice B, Rom WN, Pass HI, Kim K, Nguyen U, Taylor SL, Gandara DR, Kelly K, Fiehn O, Miyamoto S. Metabolomic markers of altered nucleotide metabolism in early stage adenocarcinoma. Cancer Prev Res (Phila). 2015 May; 8(5):410-8. PMID: 25657018.
      View in: PubMed
    95. Ou SH, Moon J, Garland LL, Mack PC, Testa JR, Tsao AS, Wozniak AJ, Gandara DR. SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol. 2015 Feb; 10(2):387-91. PMID: 25611229; PMCID: PMC4304604.
    96. Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, Villalona-Calero MA, Morgan RJ, Szabo PM, Youn A, Chen AP, Ji J, Allen DE, Lih CJ, Mehaffey MG, Walsh WD, McGregor PM, Steinberg SM, Williams PM, Kinders RJ, Conley BA, Simon RM, Doroshow JH. Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer. Clin Cancer Res. 2015 Apr 01; 21(7):1574-82. PMID: 25589624.
      View in: PubMed
    97. Wozniak AJ, Moon J, Thomas CR, Kelly K, Mack PC, Gaspar LE, Raben D, Fitzgerald TJ, Pandya KJ, Gandara DR. A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer. 2015 Sep; 16(5):340-7. PMID: 25703100; PMCID: PMC4497941.
    98. Lara PN, Moon J, Redman MW, Semrad TJ, Kelly K, Allen JW, Gitlitz BJ, Mack PC, Gandara DR. Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. J Thorac Oncol. 2015 Jan; 10(1):110-5. PMID: 25490004; PMCID: PMC4320001.
    99. Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara DR, Patnaik A, Baird RD, Olmos D, Garrett CR, Skolnik JM, Rubin EH, Smith PD, Huang P, Learoyd M, Shannon KA, Morosky A, Tetteh E, Jou YM, Papadopoulos KP, Moreno V, Kaiser B, Yap TA, Yan L, de Bono JS. Antitumor activity in RAS-driven tumors by blocking AKT and MEK. Clin Cancer Res. 2015 Feb 15; 21(4):739-48. PMID: 25516890; PMCID: PMC4335074.
    100. Koczywas M, Frankel PH, Synold TW, Lenz HJ, Mortimer JE, El-Khoueiry AB, Gandara DR, Cristea MC, Chung VM, Lim D, Reckamp KL, Lau DH, Doyle LA, Ruel C, Carroll MI, Newman EM. Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors. Br J Cancer. 2014 Dec 09; 111(12):2268-74. PMID: 25349975.
      View in: PubMed
    101. Holland WS, Chinn DC, Lara PN, Gandara DR, Mack PC. Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines. J Cancer Res Clin Oncol. 2015 Apr; 141(4):615-26. PMID: 25323938; PMCID: PMC4562434.
    102. Allen JW, Moon J, Redman M, Gadgeel SM, Kelly K, Mack PC, Saba HM, Mohamed MK, Jahanzeb M, Gandara DR. Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol. 2014 Aug 10; 32(23):2463-70. PMID: 25002722; PMCID: PMC4121504.
    103. Kernstine KH, Moon J, Kraut MJ, Pisters KM, Sonett JR, Rusch VW, Thomas CR, Waddell TK, Jett JR, Lyss AP, Keller SM, Gandara DR. Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220. Ann Thorac Surg. 2014 Aug; 98(2):402-10. PMID: 24980603.
      View in: PubMed
    104. Lara MS, Brunson A, Wun T, Tomlinson B, Qi L, Cress R, Gandara DR, Kelly K. Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): a California Cancer Registry analysis. Lung Cancer. 2014 Aug; 85(2):264-9. PMID: 24878033.
      View in: PubMed
    105. Bepler G, Zinner RG, Moon J, Calhoun R, Kernstine K, Williams CC, Mack PC, Oliveira V, Zheng Z, Stella PJ, Redman MW, Gandara DR. A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer. 2014 Aug 01; 120(15):2343-51. PMID: 24752945; PMCID: PMC4140446.
    106. Cooke DT, Gandara DR, Goodwin NC, Calhoun RF, Lara PN, Mack PC, David EA. Outcomes and efficacy of thoracic surgery biopsy for tumor molecular profiling in patients with advanced lung cancer. J Thorac Cardiovasc Surg. 2014 Jul; 148(1):36-40. PMID: 24746995.
      View in: PubMed
    107. Li T, Maus MK, Desai SJ, Beckett LA, Stephens C, Huang E, Hsiang J, Zeger G, Danenberg KD, Astrow SH, Gandara DR. Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. J Thorac Oncol. 2014 Jan; 9(1):18-25. PMID: 24346090.
      View in: PubMed
    108. Kim ES, Moon J, Herbst RS, Redman MW, Dakhil SR, Velasco MR, Hirsch FR, Mack PC, Kelly K, Heymach JV, Gandara DR. Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536. J Thorac Oncol. 2013 Dec; 8(12):1519-28. PMID: 24189513; PMCID: PMC4072123.
    109. Maus MK, Grimminger PP, Mack PC, Astrow SH, Stephens C, Zeger G, Hsiang J, Brabender J, Friedrich M, Alakus H, Hölscher AH, Lara P, Danenberg KD, Lenz HJ, Gandara DR. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies. Lung Cancer. 2014 Feb; 83(2):163-7. PMID: 24331409.
      View in: PubMed
    110. Gandara DR, Li T, Lara PN, Kelly K, Riess JW, Redman MW, Mack PC. Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. Clin Lung Cancer. 2014 Jan; 15(1):1-6. PMID: 24176733; PMCID: PMC4586161.
    111. Lwin Z, Riess JW, Gandara D. The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era. J Thorac Dis. 2013 Oct; 5 Suppl 5:S556-64. PMID: 24163748; PMCID: PMC3804876.
    112. Ho C, Davies AM, Sangha RS, Lau D, Lara P, Chew HK, Beckett L, Mack PC, Riess JW, Gandara DR. Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer. Invest New Drugs. 2013 Dec; 31(6):1587-91. PMID: 24013936; PMCID: PMC4562389.
    113. Chen Y, Moon J, Pandya KJ, Lau DH, Kelly K, Hirsch FR, Gaspar LE, Redman M, Gandara DR. A Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Cell Lung Cancer. Front Oncol. 2013; 3:219. PMID: 24010120; PMCID: PMC3755267.
    114. Goss GD, O'Callaghan C, Lorimer I, Tsao MS, Masters GA, Jett J, Edelman MJ, Lilenbaum R, Choy H, Khuri F, Pisters K, Gandara D, Kernstine K, Butts C, Noble J, Hensing TA, Rowland K, Schiller J, Ding K, Shepherd FA. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol. 2013 Sep 20; 31(27):3320-6. PMID: 23980091; PMCID: PMC3770864.
    115. Kelly K, Chansky K, Mack PC, Lara PN, Hirsch FR, Franklin WA, Wozniak AJ, Edelman MJ, Williamson SK, Gandara DR. Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy. Clin Lung Cancer. 2013 Nov; 14(6):627-35. PMID: 23910067; PMCID: PMC4122504.
    116. Hirsch FR, Gandara DR. FASTACT-2: but don't act too fast. Lancet Oncol. 2013 Jul; 14(8):684-5. PMID: 23782815.
      View in: PubMed
    117. Iqbal S, Lenz HJ, Gandara DR, Shibata SI, Groshen S, Synold TW, Newman EM. A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Jul; 72(1):85-91. PMID: 23712328; PMCID: PMC3779138.
    118. Maus MK, Mack PC, Astrow SH, Stephens CL, Zeger GD, Grimminger PP, Hsiang JH, Huang E, Li T, Lara PN, Danenberg KD, Gandara DR. Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy. J Thorac Oncol. 2013 May; 8(5):582-6. PMID: 23470290.
      View in: PubMed
    119. Ruhaak LR, Taylor SL, Miyamoto S, Kelly K, Leiserowitz GS, Gandara D, Lebrilla CB, Kim K. Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses. Anal Bioanal Chem. 2013 May; 405(14):4953-8. PMID: 23525540; PMCID: PMC3640767.
    120. Hirsch FR, Jänne PA, Eberhardt WE, Cappuzzo F, Thatcher N, Pirker R, Choy H, Kim ES, Paz-Ares L, Gandara DR, Wu YL, Ahn MJ, Mitsudomi T, Shepherd FA, Mok TS. Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol. 2013 Mar; 8(3):373-84. PMID: 23370315.
      View in: PubMed
    121. Lau DH, Moon J, Davies AM, Sanborn RE, Hirsch FR, Franklin WA, Ruzich JC, Redman MW, Gandara DR. Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma. Clin Lung Cancer. 2013 Jul; 14(4):351-5. PMID: 23415808; PMCID: PMC4567037.
    122. Schiller JH, Gandara DR, Goss GD, Vokes EE. Non-small-cell lung cancer: then and now. J Clin Oncol. 2013 Mar 10; 31(8):981-3. PMID: 23401450.
      View in: PubMed
    123. Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013 Mar 10; 31(8):1039-49. PMID: 23401433; PMCID: PMC3589700.
    124. Mack PC, Gandara DR, Lara PN. Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the 'common arm' approach. Expert Rev Anticancer Ther. 2012 Dec; 12(12):1591-6. PMID: 23253224.
      View in: PubMed
    125. Tuscano JM, Kato J, Pearson D, Xiong C, Newell L, Ma Y, Gandara DR, O'Donnell RT. CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy. Cancer Res. 2012 Nov 01; 72(21):5556-65. PMID: 22986740.
      View in: PubMed
    126. Campbell NP, Kunnavakkam R, Leighl N, Vincent MD, Gandara DR, Koczywas M, Gitlitz BJ, Agamah E, Thomas SP, Stadler WM, Vokes EE, Kindler HL. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012 Oct; 78(1):76-80. PMID: 22831987.
      View in: PubMed
    127. Gandara DR, Li T, Lara PN, Mack PC, Kelly K, Miyamoto S, Goodwin N, Beckett L, Redman MW. Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity. Clin Lung Cancer. 2012 Sep; 13(5):321-5. PMID: 22677432; PMCID: PMC4049356.
    128. Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Jänne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012 Jul 10; 30(20):2509-15. PMID: 22665541; PMCID: PMC3397785.
    129. Redman MW, Crowley JJ, Herbst RS, Hirsch FR, Gandara DR. Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819. Clin Cancer Res. 2012 Aug 01; 18(15):4004-12. PMID: 22592956; PMCID: PMC3409929.
    130. Qi Y, Allen Ziegler KL, Hillman SL, Redman MW, Schild SE, Gandara DR, Adjei AA, Mandrekar SJ. Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer. Cancer. 2012 Nov 01; 118(21):5358-65. PMID: 22434489; PMCID: PMC3481159.
    131. Gitlitz BJ, Tsao-Wei DD, Groshen S, Davies A, Koczywas M, Belani CP, Argiris A, Ramalingam S, Vokes EE, Edelman M, Hoffman P, Ballas MS, Liu SV, Gandara DR. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. J Thorac Oncol. 2012 Mar; 7(3):574-8. PMID: 22198425; PMCID: PMC3288403.
    132. Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, Gandara DR, Allen D, Kiesel B, Beumer JH, Newman EM, Rubinstein L, Chen A, Zhang Y, Wang L, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res. 2012 Mar 15; 18(6):1726-34. PMID: 22307137.
      View in: PubMed
    133. Mahaffey CM, Mahaffey NC, Holland W, Zhang H, Gandara DR, Mack PC, Forman HJ. Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma. J Thorac Oncol. 2012 Jan; 7(1):34-9. PMID: 22089114; PMCID: PMC3241903.
    134. Sangha R, Davies AM, Lara PN, Mack PC, Beckett LA, Hesketh PJ, Lau D, Li T, Perkins N, Gandara DR. Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial. J Thorac Oncol. 2011 Dec; 6(12):2112-9. PMID: 21892109; PMCID: PMC3219834.
    135. Chao J, Synold TW, Morgan RJ, Kunos C, Longmate J, Lenz HJ, Lim D, Shibata S, Chung V, Stoller RG, Belani CP, Gandara DR, McNamara M, Gitlitz BJ, Lau DH, Ramalingam SS, Davies A, Espinoza-Delgado I, Newman EM, Yen Y. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study. Cancer Chemother Pharmacol. 2012 Mar; 69(3):835-43. PMID: 22105720; PMCID: PMC3288125.
    136. Garland LL, Chansky K, Wozniak AJ, Tsao AS, Gadgeel SM, Verschraegen CF, Dasilva MA, Redman M, Gandara DR. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J Thorac Oncol. 2011 Nov; 6(11):1938-45. PMID: 21964533; PMCID: PMC3477852.
    137. Semrad TJ, Eddings C, Pan CX, Lau DH, Gandara D, Beckett L, Lara PN. Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors. Invest New Drugs. 2012 Oct; 30(5):2001-7. PMID: 22015991; PMCID: PMC4131984.
    138. Ramalingam SS, Davies AM, Longmate J, Edelman MJ, Lara PN, Vokes EE, Villalona-Calero M, Gitlitz B, Reckamp K, Salgia R, Wright JJ, Belani CP, Gandara DR. Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). J Thorac Oncol. 2011 Oct; 6(10):1741-5. PMID: 21716143; PMCID: PMC3220078.
    139. Tarhini AA, Frankel P, Margolin KA, Christensen S, Ruel C, Shipe-Spotloe J, Gandara DR, Chen A, Kirkwood JM. Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin. Clin Cancer Res. 2011 Oct 15; 17(20):6574-81. PMID: 21880788; PMCID: PMC3196047.
    140. Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC, Thertulien R, Wertheim M, Mazieres J, Hensing T, Lee C, Gupta N, Pradhan R, Qian J, Qin Q, Scappaticci FA, Ricker JL, Carlson DM, Soo RA. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011 Aug; 6(8):1418-25. PMID: 21597387.
      View in: PubMed
    141. Holland WS, Tepper CG, Pietri JE, Chinn DC, Gandara DR, Mack PC, Lara PN. Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy. Cancer Chemother Pharmacol. 2012 Jan; 69(1):185-94. PMID: 21644050; PMCID: PMC4562405.
    142. Somlo G, Lashkari A, Bellamy W, Zimmerman TM, Tuscano JM, O'Donnell MR, Mohrbacher AF, Forman SJ, Frankel P, Chen HX, Doroshow JH, Gandara DR. Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial. Br J Haematol. 2011 Aug; 154(4):533-5. PMID: 21517811; PMCID: PMC3272081.
    143. Shek D, Longmate J, Quinn DI, Margolin KA, Twardowski P, Gandara DR, Frankel P, Pan CX, Lara PN. A phase II trial of gefitinib and pegylated IFNa in previously treated renal cell carcinoma. Int J Clin Oncol. 2011 Oct; 16(5):494-9. PMID: 21431345.
      View in: PubMed
    144. El-Khoueiry AB, Ramanathan RK, Yang DY, Zhang W, Shibata S, Wright JJ, Gandara D, Lenz HJ. A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. Invest New Drugs. 2012 Jun; 30(3):1175-83. PMID: 21424698.
      View in: PubMed
    145. Henderson PT, Li T, He M, Zhang H, Malfatti M, Gandara D, Grimminger PP, Danenberg KD, Beckett L, de Vere White RW, Turteltaub KW, Pan CX. A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance. Int J Cancer. 2011 Sep 15; 129(6):1425-34. PMID: 21128223; PMCID: PMC3145006.
    146. Rothschild SI, Gautschi O, Lara PN, Mack PC, Gandara DR. Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer. Curr Opin Oncol. 2011 Mar; 23(2):150-7. PMID: 21119513.
      View in: PubMed
    147. Semrad TJ, Gandara DR, Lara PN. Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience. Ther Adv Med Oncol. 2011 Mar; 3(2):95-100. PMID: 21789159; PMCID: PMC3126039.
    148. Tsao AS, Garland L, Redman M, Kernstine K, Gandara D, Marom EM. A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria. J Thorac Oncol. 2011 Mar; 6(3):598-601. PMID: 21270668; PMCID: PMC3643692.
    149. Kirschbaum M, Frankel P, Popplewell L, Zain J, Delioukina M, Pullarkat V, Matsuoka D, Pulone B, Rotter AJ, Espinoza-Delgado I, Nademanee A, Forman SJ, Gandara D, Newman E. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2011 Mar 20; 29(9):1198-203. PMID: 21300924; PMCID: PMC3083875.
    150. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, Xiong H, Krivoshik AP, Humerickhouse R, Shapiro GI, Rudin CM. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011 Mar 01; 29(7):909-16. PMID: 21282543.
      View in: PubMed
    151. Tsao MS, Sakurada A, Ding K, Aviel-Ronen S, Ludkovski O, Liu N, Le Maître A, Gandara D, Johnson DH, Rigas JR, Seymour L, Shepherd FA. Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer. J Thorac Oncol. 2011 Jan; 6(1):139-47. PMID: 21107284; PMCID: PMC3033998.
    152. Blanchard EM, Moon J, Hesketh PJ, Kelly K, Wozniak AJ, Crowley J, Gandara D. Comparison of platinum-based chemotherapy in patients older and younger than 70 years: an analysis of Southwest Oncology Group Trials 9308 and 9509. J Thorac Oncol. 2011 Jan; 6(1):115-20. PMID: 21107287; PMCID: PMC3075557.
    153. Lara PN, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S, Belani CP, Mack PC, Lau DH, Koczywas M, Wright JJ, Shepherd FA, Leighl N, Gandara DR. Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. Clin Lung Cancer. 2011 Jan; 12(1):33-7. PMID: 21273177; PMCID: PMC3777729.
    154. Gandara DR, Grimminger P, Mack PC, Lara PN, Li T, Danenberg PV, Danenberg KD. Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer. J Thorac Oncol. 2010 Dec; 5(12):1933-8. PMID: 20975603.
      View in: PubMed
    155. Gitlitz BJ, Moon J, Glisson BS, Reimers HJ, Bury MJ, Floyd JD, Schulz TK, Sundaram PK, Ho C, Gandara DR. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol. 2010 Nov; 5(11):1835-40. PMID: 20881645; PMCID: PMC3676180.
    156. Suga JM, Nguyen DV, Mohammed SM, Brown M, Calhoun R, Yoneda K, Gandara DR, Lara PN. Racial disparities on the use of invasive and noninvasive staging in patients with non-small cell lung cancer. J Thorac Oncol. 2010 Nov; 5(11):1772-8. PMID: 20881638.
      View in: PubMed
    157. Li T, Christensen SD, Frankel PH, Margolin KA, Agarwala SS, Luu T, Mack PC, Lara PN, Gandara DR. A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial. Invest New Drugs. 2012 Apr; 30(2):741-8. PMID: 20967484; PMCID: PMC3277821.
    158. Morgan RJ, Leong L, Chow W, Gandara D, Frankel P, Garcia A, Lenz HJ, Doroshow JH. Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study. Invest New Drugs. 2012 Apr; 30(2):723-8. PMID: 20936324.
      View in: PubMed
    159. Hirsch FR, Wynes MW, Gandara DR, Bunn PA. The tissue is the issue: personalized medicine for non-small cell lung cancer. Clin Cancer Res. 2010 Oct 15; 16(20):4909-11. PMID: 20926402.
      View in: PubMed
    160. Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES, Redman M, Crowley JJ, Gandara DR. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. J Clin Oncol. 2010 Nov 01; 28(31):4747-54. PMID: 20921467; PMCID: PMC3020704.
    161. Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, Hirsch FR, Grunenwald D, Popper H, Smit E, Dietel M, Marchetti A, Manegold C, Schirmacher P, Thomas M, Rosell R, Cappuzzo F, Stahel R. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol. 2010 Oct; 5(10):1706-13. PMID: 20871269.
      View in: PubMed
    162. Lara PN, Chansky K, Shibata T, Fukuda H, Tamura T, Crowley J, Redman MW, Natale R, Saijo N, Gandara DR. Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124. Cancer. 2010 Dec 15; 116(24):5710-5. PMID: 20737417; PMCID: PMC2994945.
    163. Ramalingam SS, Belani CP, Mack PC, Vokes EE, Longmate J, Govindan R, Koczywas M, Ivy SP, Gandara DR. Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol. 2010 Aug; 5(8):1279-84. PMID: 20559150; PMCID: PMC2911495.
    164. Twardowski P, Stadler WM, Frankel P, Lara PN, Ruel C, Chatta G, Heath E, Quinn DI, Gandara DR. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology. 2010 Oct; 76(4):923-6. PMID: 20646741; PMCID: PMC2952720.
    165. Pisters KM, Vallières E, Crowley JJ, Franklin WA, Bunn PA, Ginsberg RJ, Putnam JB, Chansky K, Gandara D. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol. 2010 Apr 10; 28(11):1843-9. PMID: 20231678; PMCID: PMC2860367.
    166. Gandara DR, Mack PC, Li T, Lara PN, Herbst RS. [Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012]. Zhongguo Fei Ai Za Zhi. 2010 Mar; 13(3):238-41. PMID: 20681067.
      View in: PubMed
    167. Ho C, Sangha R, Beckett L, Tanaka M, Lau DH, Eisen DB, Burich RA, Luciw P, Khan I, Mack PC, Gandara DR, Davies AM. Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I study. Invest New Drugs. 2011 Aug; 29(4):680-7. PMID: 20148348; PMCID: PMC4559347.
    168. Li T, Lara PN, Mack PC, Perez-Soler R, Gandara DR. Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer. Curr Drug Targets. 2010 Jan; 11(1):85-94. PMID: 19839922.
      View in: PubMed
    169. Mack PC, Holland WS, Burich RA, Sangha R, Solis LJ, Li Y, Beckett LA, Lara PN, Davies AM, Gandara DR. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol. 2009 Dec; 4(12):1466-72. PMID: 19884861.
      View in: PubMed
    170. Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B, Thomas S, Espinoza-Delgado I, Vokes EE, Gandara DR, Belani CP. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol. 2010 Jan 01; 28(1):56-62. PMID: 19933908; PMCID: PMC2799233.
    171. Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, Johnson DH, Kesler KA, Green M, Vincent M, Cormier Y, Goss G, Findlay B, Johnston M, Tsao MS, Shepherd FA. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol. 2010 Jan 01; 28(1):29-34. PMID: 19933915; PMCID: PMC2799232.
    172. Wakelee H, Loo BW, Kernstine KH, Putnam JB, Edelman MJ, Vokes EE, Schiller JH, Baas P, Saijo N, Adjei A, Goss G, Choy H, Gandara DR. Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress. Clin Lung Cancer. 2009 Nov; 10(6):395-404. PMID: 19900856.
      View in: PubMed
    173. Gandara DR, Mack PC, Li T, Lara PN, Herbst RS. Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012. Clin Lung Cancer. 2009 Nov; 10(6):392-4. PMID: 19900855.
      View in: PubMed
    174. Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Adjei AA, Gandara DR, Ziegler KL, Stella PJ, Rowland KM, Schild SE, Zinner RG. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol. 2010 Feb 01; 28(4):614-9. PMID: 19841321; PMCID: PMC2815996.
    175. Sangha R, Lara PN, Adjei AA, Baas P, Choy H, Gaspar LE, Goss G, Saijo N, Schiller JH, Vokes EE, Gandara DR. Cooperative group research endeavors in small-cell lung cancer: current and future directions. Clin Lung Cancer. 2009 Sep; 10(5):322-30. PMID: 19808190.
      View in: PubMed
    176. Albain KS, Swann RS, Rusch VW, Turrisi AT, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sause WT, Cox JD. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009 Aug 01; 374(9687):379-86. PMID: 19632716; PMCID: PMC4407808.
    177. Davies AM, Ho C, Beckett L, Lau D, Scudder SA, Lara PN, Perkins N, Gandara DR. Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation. J Thorac Oncol. 2009 Jul; 4(7):862-8. PMID: 19494788.
      View in: PubMed
    178. Gandara DR, Simons J. A decade of clinical lung cancer. Clin Lung Cancer. 2009 Jul; 10(4):216. PMID: 19632936.
      View in: PubMed
    179. Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK, Gautschi O, Lenz HJ, McLeod HL, Lara PN, Coltman CA, Fukuoka M, Saijo N, Fukushima M, Mack PC. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol. 2009 Jul 20; 27(21):3540-6. PMID: 19470925.
      View in: PubMed
    180. Gandara DR, Lara PN, Mack P, Scagliotti G. Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making. Clin Lung Cancer. 2009 May; 10(3):148-50. PMID: 19443333.
      View in: PubMed
    181. Le QT, Moon J, Redman M, Williamson SK, Lara PN, Goldberg Z, Gaspar LE, Crowley JJ, Moore DF, Gandara DR. Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. J Clin Oncol. 2009 Jun 20; 27(18):3014-9. PMID: 19364954.
      View in: PubMed
    182. Lara PN, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009 May 20; 27(15):2530-5. PMID: 19349543; PMCID: PMC2684855.
    183. Purnell PR, Mack PC, Tepper CG, Evans CP, Green TP, Gumerlock PH, Lara PN, Gandara DR, Kung HJ, Gautschi O. The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. J Thorac Oncol. 2009 Apr; 4(4):448-54. PMID: 19240653; PMCID: PMC2716757.
    184. Shibata SI, Doroshow JH, Frankel P, Synold TW, Yen Y, Gandara DR, Lenz HJ, Chow WA, Leong LA, Lim D, Margolin KA, Morgan RJ, Somlo G, Newman EM. Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study. Cancer Chemother Pharmacol. 2009 Nov; 64(6):1149-55. PMID: 19322566; PMCID: PMC3046108.
    185. Chew HK, Doroshow JH, Frankel P, Margolin KA, Somlo G, Lenz HJ, Gordon M, Zhang W, Yang D, Russell C, Spicer D, Synold T, Bayer R, Hantel A, Stiff PJ, Tetef ML, Gandara DR, Albain KS. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol. 2009 May 01; 27(13):2163-9. PMID: 19307510; PMCID: PMC2674003.
    186. Lara PN, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G, Posadas E, Stadler W, Gandara DR. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs. 2009 Mar; 20(3):179-84. PMID: 19396016; PMCID: PMC3225398.
    187. Sangha R, Lara PN, Mack PC, Gandara DR. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier. Curr Opin Oncol. 2009 Mar; 21(2):116-23. PMID: 19532012.
      View in: PubMed
    188. Chen G, Huynh M, Fehrenbacher L, West H, Lara PN, Yavorkovsky LL, Russin M, Goldstein D, Gandara D, Lau D. Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. J Clin Oncol. 2009 Mar 20; 27(9):1401-4. PMID: 19204194; PMCID: PMC2668551.
    189. Ramanathan RK, Belani CP, Singh DA, Tanaka M, Lenz HJ, Yen Y, Kindler HL, Iqbal S, Longmate J, Mack PC, Lurje G, Gandour-Edwards R, Dancey J, Gandara DR. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009 Sep; 64(4):777-83. PMID: 19169683.
      View in: PubMed
    190. Cheung E, Pinski J, Dorff T, Groshen S, Quinn DI, Reynolds CP, Maurer BJ, Lara PN, Tsao-Wei DD, Twardowski P, Chatta G, McNamara M, Gandara DR. Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial. Clin Genitourin Cancer. 2009 Jan; 7(1):43-50. PMID: 19213668.
      View in: PubMed
    191. Ramalingam SS, Belani CP, Ruel C, Frankel P, Gitlitz B, Koczywas M, Espinoza-Delgado I, Gandara D. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol. 2009 Jan; 4(1):97-101. PMID: 19096314; PMCID: PMC3263397.
    192. Davies AM, Chansky K, Lara PN, Gumerlock PH, Crowley J, Albain KS, Vogel SJ, Gandara DR. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol. 2009 Jan; 4(1):87-92. PMID: 19096312; PMCID: PMC3024911.
    193. Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia AA, Morgan R, Gandara D, Scudder S, Oza A, Hirte H, Fleming G, Roman L, Lenz HJ. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res. 2008 Nov 15; 14(22):7554-63. PMID: 19010874; PMCID: PMC2586993.
    194. Wakelee H, Kernstine K, Vokes E, Schiller J, Baas P, Saijo N, Adjei A, Goss G, Gaspar L, Gandara DR, Choy H, Putnam JB. Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer. Clin Lung Cancer. 2008 Nov; 9(6):346-51. PMID: 19073517.
      View in: PubMed
    195. Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, Frankel P, Smith DD, Doroshow JH, Wong C, Aparicio A, Gandara DR, Somlo G. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res. 2008 Nov 01; 14(21):7138-42. PMID: 18981013; PMCID: PMC3543872.
    196. Gandara DR, Lara PN, Natale R, Belani C. Progress in small-cell lung cancer: the lowest common denominator. J Clin Oncol. 2008 Sep 10; 26(26):4236-8. PMID: 18779609.
      View in: PubMed
    197. Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN, Franklin WA, Le QT, Crowley JJ, Gandara DR. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol. 2008 Oct 10; 26(29):4771-6. PMID: 18779603; PMCID: PMC2653139.
    198. Hesketh PJ, Chansky K, Wozniak AJ, Hirsch FR, Spreafico A, Moon J, Mack PC, Marchello BT, Franklin WA, Crowley JJ, Gandara DR. Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2. J Thorac Oncol. 2008 Sep; 3(9):1026-31. PMID: 18758306.
      View in: PubMed
    199. Raz DJ, Ray MR, Kim JY, He B, Taron M, Skrzypski M, Segal M, Gandara DR, Rosell R, Jablons DM. A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clin Cancer Res. 2008 Sep 01; 14(17):5565-70. PMID: 18765549.
      View in: PubMed
    200. Yen Y, Lim DW, Chung V, Morgan RJ, Leong LA, Shibata SI, Wagman LD, Wagman SD, Marx H, Chu PG, Longmate JA, Lenz HJ, Ramanathan RK, Belani CP, Gandara DR. Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial. Am J Clin Oncol. 2008 Aug; 31(4):317-22. PMID: 18845988.
      View in: PubMed
    201. Chee KG, Nguyen DV, Brown M, Gandara DR, Wun T, Lara PN. Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited. Arch Intern Med. 2008 Jul 28; 168(14):1541-9. PMID: 18663166.
      View in: PubMed
    202. Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA, Varella-Garcia M, Gandara DR. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol. 2008 Jul 10; 26(20):3351-7. PMID: 18612151; PMCID: PMC3368372.
    203. Lau D, Johl J, Huynh M, Davies A, Tanaka M, Lara P, Gandara D. Population-based phase I trial of irinotecan and epirubicin. Am J Clin Oncol. 2008 Jun; 31(3):226-30. PMID: 18525299.
      View in: PubMed
    204. Hirsch FR, Dziadziuszko R, Varella-Garcia M, Franklin WA, Gandara DR, Bunn PA. First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay. J Thorac Oncol. 2008 Jun; 3(6 Suppl 2):S138-42. PMID: 18520298.
      View in: PubMed
    205. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Jul 20; 26(21):3543-51. PMID: 18506025.
      View in: PubMed
    206. Einhorn LH, Bonomi P, Bunn PA, Camidge DR, Carbone DP, Choy H, Dubinett SM, Gandara DR, Gaspar LE, Govindan R, Johnson DH, Minna JD, Scagliotti G, West HJ, Herbst RS. Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer. J Thorac Oncol. 2008 May; 3(5):545-55. PMID: 18449013; PMCID: PMC3374724.
    207. Xiao GG, Zhou BS, Somlo G, Portnow J, Juhasz A, Un F, Chew H, Gandara D, Yen Y. Identification of F-box/LLR-repeated protein 17 as potential useful biomarker for breast cancer therapy. Cancer Genomics Proteomics. 2008 May-Aug; 5(3-4):151-60. PMID: 18820369.
      View in: PubMed
    208. Calhoun R, Jablons D, Lau D, Gandara DR. Adjuvant treatment of stage IB NSCLC: the problem of stage subset heterogeneity. Oncology (Williston Park). 2008 Apr 30; 22(5):511-6; discussion 516, 521-3. PMID: 18533401.
      View in: PubMed
    209. Gautschi O, Tepper CG, Purnell PR, Izumiya Y, Evans CP, Green TP, Desprez PY, Lara PN, Gandara DR, Mack PC, Kung HJ. Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer Res. 2008 Apr 01; 68(7):2250-8. PMID: 18381431.
      View in: PubMed
    210. Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DH, Crowley JJ, Gandara DR. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008 May 20; 26(15):2450-6. PMID: 18378568.
      View in: PubMed
    211. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res. 2008 Mar 15; 14(6):1639-48. PMID: 18347165.
      View in: PubMed
    212. Langer CJ, Wakelee H, Schiller J, Choy H, Shepherd F, Vokes EE, Adjei AA, Baas P, Saijo N, Gandara DR. Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress? Clin Lung Cancer. 2008 Mar; 9(2):85-91. PMID: 18501094.
      View in: PubMed
    213. Lara PN, Redman MW, Kelly K, Edelman MJ, Williamson SK, Crowley JJ, Gandara DR. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol. 2008 Jan 20; 26(3):463-7. PMID: 18202421.
      View in: PubMed
    214. Sangha R, Lara PN, Mack P, Gandara DR. Targeted therapies in non-small-cell lung cancer: a paradigm in evolution. Clin Lung Cancer. 2008; 9 Suppl 3:S90-1. PMID: 19419929.
      View in: PubMed
    215. Wakelee H, Langer C, Vokes E, Schiller J, Baas P, Saijo N, Adjei A, Shepherd F, Choy H, Gandara DR. Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancer. Clin Lung Cancer. 2008 Jan; 9(1):9-15. PMID: 18282352.
      View in: PubMed
    216. Davies AM, Ruel C, Lara PN, Lau DH, Gumerlock PH, Bold R, Shibata S, Lenz HJ, Schenkein DP, Gandara DR. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. J Thorac Oncol. 2008 Jan; 3(1):68-74. PMID: 18166843.
      View in: PubMed
    217. Gautschi O, Mack PC, Davies AM, Jablons DM, Rosell R, Gandara DR. Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directions. Clin Lung Cancer. 2008; 9 Suppl 3:S129-38. PMID: 19419927.
      View in: PubMed
    218. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz HJ, Oza AM. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008 Jan 01; 26(1):76-82. PMID: 18165643.
      View in: PubMed
    219. Umutyan A, Chiechi C, Beckett LA, Paterniti DA, Turrell C, Gandara DR, Davis SW, Wun T, Chen MS, Lara PN. Overcoming barriers to cancer clinical trial accrual: impact of a mass media campaign. Cancer. 2008 Jan 01; 112(1):212-9. PMID: 18008353.
      View in: PubMed
    220. Chen G, Huynh M, Chen A, Fehrenbacher L, Gandara D, Lau D. Chemotherapy for brain metastases in small-cell lung cancer. Clin Lung Cancer. 2008 Jan; 9(1):35-8. PMID: 18282356.
      View in: PubMed
    221. Davies AM, Ho C, Metzger AS, Beckett LA, Christensen S, Tanaka M, Lara PN, Lau DH, Gandara DR. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. J Thorac Oncol. 2007 Dec; 2(12):1112-6. PMID: 18090584.
      View in: PubMed
    222. Chee KG, Longmate J, Quinn DI, Chatta G, Pinski J, Twardowski P, Pan CX, Cambio A, Evans CP, Gandara DR, Lara PN. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer. 2007 Dec; 5(7):433-7. PMID: 18272025.
      View in: PubMed
    223. Mahaffey CM, Davies AM, Lara PN, Pryde B, Holland W, Mack PC, Gumerlock PH, Gandara DR. Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin Lung Cancer. 2007 Nov; 8(9):548-53. PMID: 18186959.
      View in: PubMed
    224. Gandara DR, Sangha R, Davies AM. Bevacizumab: optimal dose, schedule, and duration of therapy. Clin Lung Cancer. 2007 Nov; 8(9):522-3. PMID: 18186957.
      View in: PubMed
    225. Davies AM, Lara PN, Mack PC, Gandara DR. Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res. 2007 Aug 01; 13(15 Pt 2):s4647-51. PMID: 17671158.
      View in: PubMed
    226. Ho C, Davies A, Mack P, Gandara D. Dual inhibition: combining epidermal growth factor-targeted therapies in non-small-cell lung cancer. Clin Lung Cancer. 2007 Jul; 8(7):420-4. PMID: 17681094.
      View in: PubMed
    227. Gandara DR, Wakelee H, Calhoun R, Jablons D. Adjuvant chemotherapy of stage I non-small cell lung cancer in North America. J Thorac Oncol. 2007 Jul; 2(7 Suppl 3):S125-7. PMID: 17603308.
      View in: PubMed
    228. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G, Muñoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D, Rosell R. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 2007 Jul 01; 25(19):2747-54. PMID: 17602080.
      View in: PubMed
    229. Synold TW, Takimoto CH, Doroshow JH, Gandara D, Mani S, Remick SC, Mulkerin DL, Hamilton A, Sharma S, Ramanathan RK, Lenz HJ, Graham M, Longmate J, Kaufman BM, Ivy P. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res. 2007 Jun 15; 13(12):3660-6. PMID: 17575231.
      View in: PubMed
    230. Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, Klein-Szanto AJ, Testa JR, Altomare DA, Borden EC. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol. 2007 Jun 10; 25(17):2406-13. PMID: 17557954.
      View in: PubMed
    231. Akerley W, McCoy J, Hesketh PJ, Goodwin JW, Bearden JD, Atkins JN, Chansky K, Crowley JJ, Gandara DR. Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119. J Thorac Oncol. 2007 Jun; 2(6):526-30. PMID: 17545848.
      View in: PubMed
    232. Yoneda KY, Shelton DK, Beckett LA, Gandara DR. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. J Thorac Oncol. 2007 Jun; 2(6):537-43. PMID: 17545850.
      View in: PubMed
    233. Hesketh PJ, Lilenbaum RC, Chansky K, Dowlati A, Graham P, Chapman RA, Crowley JJ, Gandara DR. Chemotherapy in patients > or = 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6. J Thorac Oncol. 2007 Jun; 2(6):494-8. PMID: 17545843.
      View in: PubMed
    234. Margolin K, Synold TW, Lara P, Frankel P, Lacey SF, Quinn DI, Baratta T, Dutcher JP, Xi B, Diamond DJ, Gandara DR. Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. J Cancer Res Clin Oncol. 2007 Oct; 133(10):705-11. PMID: 17508219.
      View in: PubMed
    235. Raz DJ, Zell JA, Ou SH, Gandara DR, Anton-Culver H, Jablons DM. Natural history of stage I non-small cell lung cancer: implications for early detection. Chest. 2007 Jul; 132(1):193-9. PMID: 17505036.
      View in: PubMed
    236. Hesketh PJ, Chansky K, Israel V, Grapski RT, Mekhail TM, Spiridonidis CH, Mills GM, Kelly K, Crowley JJ, Gandara DR. Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718. J Thorac Oncol. 2007 May; 2(5):440-4. PMID: 17473660.
      View in: PubMed
    237. Gautschi O, Huegli B, Ziegler A, Gugger M, Heighway J, Ratschiller D, Mack PC, Gumerlock PH, Kung HJ, Stahel RA, Gandara DR, Betticher DC. Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett. 2007 Sep 08; 254(2):265-73. PMID: 17449174.
      View in: PubMed
    238. Davies AM, Ho C, Hesketh PJ, Beckett LA, Lara PN, Lau DH, Gandara DR. Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study. Invest New Drugs. 2007 Aug; 25(4):351-5. PMID: 17440682.
      View in: PubMed
    239. Samlowski WE, Moon J, Kuebler JP, Nichols CR, Gandara DR, Ozer H, Williamson SK, Atkins JN, Schuller DE, Ensley JF. Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study. Cancer Invest. 2007 Apr-May; 25(3):182-8. PMID: 17530488.
      View in: PubMed
    240. Morgan RJ, Synold TW, Gandara D, Muggia F, Scudder S, Reed E, Margolin K, Raschko J, Leong L, Shibata S, Tetef M, Vasilev S, McGonigle K, Longmate J, Yen Y, Chow W, Somlo G, Carroll M, Doroshow JH. Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial. Int J Gynecol Cancer. 2007 Mar-Apr; 17(2):373-8. PMID: 17362315.
      View in: PubMed
    241. Wakelee H, Dubey S, Gandara D. Optimal adjuvant therapy for non-small cell lung cancer--how to handle stage I disease. Oncologist. 2007 Mar; 12(3):331-7. PMID: 17405898.
      View in: PubMed
    242. Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC, Dziadziuszko R, Gumerlock P, Chansky K, West H, Gazdar AF, Crino L, Gandara DR, Franklin WA, Bunn PA. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol. 2007 Apr; 18(4):752-60. PMID: 17317677.
      View in: PubMed
    243. Wang H, Ryu J, Gandara D, Bold RJ, Urayama S, Tanaka M, Goldberg Z, Follette D, Narayan S, Lau D. A phase II study of paclitaxel, carboplatin, and radiation with or without surgery for esophageal cancer. J Thorac Oncol. 2007 Feb; 2(2):153-7. PMID: 17410032.
      View in: PubMed
    244. Gandara DR, Davies AM, Gautschi O, Mack PC, Lau DH, Lara PN, Hirsch FR. Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies. Clin Lung Cancer. 2007 Feb; 8 Suppl 2:S61-7. PMID: 17382026.
      View in: PubMed
    245. Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, Johnson DH, Shulman L, Shepherd F, Deschamps C, Livingston RB, Gandara D. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol. 2007 Jan 20; 25(3):313-8. PMID: 17235046.
      View in: PubMed
    246. Yoneda KY, Hardin KA, Gandara DR, Shelton DK. Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma. Clin Lung Cancer. 2006 Dec; 8 Suppl 1:S31-5. PMID: 17239288.
      View in: PubMed
    247. Davies AM, Chansky K, Lau DH, Leigh BR, Gaspar LE, Weiss GR, Wozniak AJ, Crowley JJ, Gandara DR. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. J Clin Oncol. 2006 Nov 20; 24(33):5242-6. PMID: 17114656.
      View in: PubMed
    248. Gandara DR, Aberle D, Lau D, Jett J, Akhurst T, Heelan R, Mulshine J, Berg C, Patz EF. Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. J Thorac Oncol. 2006 Nov; 1(9 Suppl):S20-6. PMID: 17409997.
      View in: PubMed
    249. Lara PN, Chansky K, Davies AM, Franklin WA, Gumerlock PH, Guaglianone PP, Atkins JN, Farneth N, Mack PC, Crowley JJ, Gandara DR. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). J Thorac Oncol. 2006 Nov; 1(9):996-1001. PMID: 17409985.
      View in: PubMed
    250. Hesketh PJ, McCoy J, Dunphy FR, Bearden JD, Weiss GR, Giguere JK, Atkins JN, Dakhil SR, Kelly K, Crowley JJ, Gandara DR. Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914. J Thorac Oncol. 2006 Nov; 1(9):991-5. PMID: 17409984.
      View in: PubMed
    251. Shibata S, Chow W, Frankel P, Juhasz A, Leong L, Lim D, Margolin K, Morgan R, Newman E, Somlo G, Yen Y, Synold T, Gandara D, Lenz HJ, Doroshow J. A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression. Cancer Chemother Pharmacol. 2007 Mar; 59(4):549-57. PMID: 17051371.
      View in: PubMed
    252. Gautschi O, Mack PC, Davies AM, Lara PN, Gandara DR. Aurora kinase inhibitors: a new class of targeted drugs in cancer. Clin Lung Cancer. 2006 Sep; 8(2):93-8. PMID: 17026809.
      View in: PubMed
    253. Gandara DR, Chansky K, Albain KS, Gaspar LE, Lara PN, Kelly K, Crowley J, Livingston R. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). Clin Lung Cancer. 2006 Sep; 8(2):116-21. PMID: 17026812.
      View in: PubMed
    254. Hesketh PJ, Chansky K, Lau DH, Doroshow JH, Moinpour CM, Chapman RA, Goodwin JW, Gross HM, Crowley JJ, Gandara DR. Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027). J Thorac Oncol. 2006 Jul; 1(6):537-44. PMID: 17409914.
      View in: PubMed
    255. Wakelee HA, Schiller JH, Gandara DR. Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial. Clin Lung Cancer. 2006 Jul; 8(1):18-21. PMID: 16870041.
      View in: PubMed
    256. Gandara DR, Davies AM. Oral second-line chemotherapy for advanced non-small-cell lung cancer: the bottom line. J Clin Oncol. 2006 Jun 20; 24(18):2700-1. PMID: 16682720.
      View in: PubMed
    257. Ho C, Davies AM, Lara PN, Gandara DR. Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options. Clin Lung Cancer. 2006 May; 7 Suppl 4:S118-25. PMID: 16764752.
      View in: PubMed
    258. Juhasz A, Vassilakos A, Chew HK, Gandara D, Yen Y. Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment. Oncol Rep. 2006 May; 15(5):1299-304. PMID: 16596201.
      View in: PubMed
    259. Davies AM, Ho C, Lara PN, Mack P, Gumerlock PH, Gandara DR. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer. 2006 May; 7(6):385-8. PMID: 16800963.
      View in: PubMed
    260. West HL, Franklin WA, McCoy J, Gumerlock PH, Vance R, Lau DH, Chansky K, Crowley JJ, Gandara DR. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol. 2006 Apr 20; 24(12):1807-13. PMID: 16622257.
      View in: PubMed
    261. Williamson SK, McCoy SA, Gandara DR, Dakhil SR, Yost KJ, Paradelo JC, Atkins JN, Blanke CD, Abbruzzese JL. Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial. Am J Clin Oncol. 2006 Apr; 29(2):116-22. PMID: 16601427.
      View in: PubMed
    262. Paz-Ares L, Douillard JY, Koralewski P, Manegold C, Smit EF, Reyes JM, Chang GC, John WJ, Peterson PM, Obasaju CK, Lahn M, Gandara DR. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2006 Mar 20; 24(9):1428-34. PMID: 16549837.
      View in: PubMed
    263. Gandara DR. Bronchioloalveolar carcinoma: the "changing face of lung cancer". Clin Lung Cancer. 2006 Mar; 7(5):299. PMID: 16640799.
      View in: PubMed
    264. Lara PN, Stadler WM, Longmate J, Quinn DI, Wexler J, Van Loan M, Twardowski P, Gumerlock PH, Vogelzang NJ, Vokes EE, Lenz HJ, Doroshow JH, Gandara DR. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res. 2006 Mar 01; 12(5):1556-63. PMID: 16533781.
      View in: PubMed
    265. Lara PN, Gandara DR, Natale RB. Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer. Clin Lung Cancer. 2006 Mar; 7(5):353-6. PMID: 16640809.
      View in: PubMed
    266. Lara PN, Koczywas M, Quinn DI, Lenz HJ, Davies AM, Lau DH, Gumerlock PH, Longmate J, Doroshow JH, Schenkein D, Kashala O, Gandara DR. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. J Thorac Oncol. 2006 Feb; 1(2):126-34. PMID: 17409841.
      View in: PubMed
    267. Williamson SK, Crowley JJ, Lara PN, McCoy J, Lau DH, Tucker RW, Mills GM, Gandara DR. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol. 2005 Dec 20; 23(36):9097-104. PMID: 16361616.
      View in: PubMed
    268. Lara PN, Paterniti DA, Chiechi C, Turrell C, Morain C, Horan N, Montell L, Gonzalez J, Davis S, Umutyan A, Martel CL, Gandara DR, Wun T, Beckett LA, Chen MS. Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. J Clin Oncol. 2005 Dec 20; 23(36):9282-9. PMID: 16361626.
      View in: PubMed
    269. Unger JM, Coltman CA, Crowley JJ, Hutchins LF, Martino S, Livingston RB, Macdonald JS, Blanke CD, Gandara DR, Crawford ED, Albain KS. Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. J Clin Oncol. 2006 Jan 01; 24(1):141-4. PMID: 16330670.
      View in: PubMed
    270. Gandara DR, Vallières E, Gaspar LE, Kelly K, Albain KS, Herbst RS, Lara PN, Mack P, Gumerlock PH, Crowley JJ. Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy. Clin Lung Cancer. 2005 Dec; 7 Suppl 3:S93-7. PMID: 16384543.
      View in: PubMed
    271. Gandara DR, Hesketh P. Treatment options for patients with advanced-stage non-small-cell lung cancer: who are the "elderly" and who are the "unfit"? Clin Lung Cancer. 2005 Nov; 7(3):154-5. PMID: 16354308.
      View in: PubMed
    272. Davies AM, Lara PN, Mack PC, Gumerlock PH, Bold RJ, Gandara DR. Bortezomib-based combinations in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 2005 Oct; 7 Suppl 2:S59-63. PMID: 16250929.
      View in: PubMed
    273. Lara PN, Bold RJ, Mack PC, Davies AM, Gumerlock PH, Gandara DR. Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications. Clin Lung Cancer. 2005 Oct; 7 Suppl 2:S67-71. PMID: 16250931.
      View in: PubMed
    274. Mortenson MM, Schlieman MG, Virudachalam S, Lara PN, Gandara DG, Davies AM, Bold RJ. Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer. Lung Cancer. 2005 Aug; 49(2):163-70. PMID: 16022909.
      View in: PubMed
    275. Gandara DR, Gumerlock PH. Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out? J Clin Oncol. 2005 Sep 01; 23(25):5856-8. PMID: 16043825.
      View in: PubMed
    276. Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, Bunn PA, Franklin WA, Crowley J, Gandara DR. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol. 2005 Oct 01; 23(28):6838-45. PMID: 15998906.
      View in: PubMed
    277. Lynch TJ, Bogart JA, Curran WJ, DeCamp MM, Gandara DR, Goss G, Henschke CI, Jett JR, Johnson BE, Kelly KL, Le Chevalier T, Mulshine JL, Scagliotti GV, Schiller JH, Shaw A, Thatcher N, Vokes EE, Wood DE, Hart C. Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):4981s-4983s. PMID: 16000599.
      View in: PubMed
    278. Gandara D, Narayan S, Lara PN, Goldberg Z, Davies A, Lau DH, Mack P, Gumerlock P, Vijayakumar S. Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):5057s-5062s. PMID: 16000614.
      View in: PubMed
    279. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, Graham B, Tsao MS, Gandara D, Kesler K, Demmy T, Shepherd F. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005 Jun 23; 352(25):2589-97. PMID: 15972865.
      View in: PubMed
    280. Lara PN, Mack PC, Synold T, Frankel P, Longmate J, Gumerlock PH, Doroshow JH, Gandara DR. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res. 2005 Jun 15; 11(12):4444-50. PMID: 15958629.
      View in: PubMed
    281. Gaspar LE, Chansky K, Albain KS, Vallieres E, Rusch V, Crowley JJ, Livingston RB, Gandara DR. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. J Clin Oncol. 2005 May 01; 23(13):2955-61. PMID: 15860851.
      View in: PubMed
    282. West HL, Crowley JJ, Vance RB, Franklin WA, Livingston RB, Dakhil SR, Giguere JK, Rivkin SE, Kraut M, Chansky K, Gandara DR. Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study. Ann Oncol. 2005 Jul; 16(7):1076-80. PMID: 15860488.
      View in: PubMed
    283. Turrisi AT, Crowley J, Albain K, Gaspar L, Gandara D. Southwest Oncology Group: two decades of experience in non-small cell lung cancer. Semin Oncol. 2005 Apr; 32(2 Suppl 3):S119-21. PMID: 16015548.
      View in: PubMed
    284. Lara PN, Law LY, Wright JJ, Frankel P, Twardowski P, Lenz HJ, Lau DH, Kawaguchi T, Gumerlock PH, Doroshow JH, Gandara DR. Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial. Anticancer Drugs. 2005 Mar; 16(3):317-21. PMID: 15711184.
      View in: PubMed
    285. Lau D, Seibert A, Gandara D, Laptalo L, Geraghty E, Coulon C. Computer-assisted image analysis of bronchioloalveolar carcinoma. Clin Lung Cancer. 2005 Mar; 6(5):281-6. PMID: 15845178.
      View in: PubMed
    286. Meyers FJ, Linder J, Beckett L, Christensen S, Blais J, Gandara DR. Simultaneous care: a model approach to the perceived conflict between investigational therapy and palliative care. J Pain Symptom Manage. 2004 Dec; 28(6):548-56. PMID: 15589080.
      View in: PubMed
    287. Mack PC, Jones AA, Gustafsson MH, Gandara DR, Gumerlock PH, Goldberg Z. Enhancement of radiation cytotoxicity by UCN-01 in non-small cell lung carcinoma cells. Radiat Res. 2004 Dec; 162(6):623-34. PMID: 15548112.
      View in: PubMed
    288. Lau D, Guo L, Gandara D, Young LJ, Xue L. Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent? Anticancer Drugs. 2004 Oct; 15(9):871-5. PMID: 15457127.
      View in: PubMed
    289. Martel CL, Li Y, Beckett L, Chew H, Christensen S, Davies A, Lam KS, Lau DH, Meyers FJ, O'donnell RT, Richman C, Scudder S, Tanaka M, Tuscano J, Welborn J, Wun T, Gandara DR, Lara PN. An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California. Cancer J. 2004 Sep-Oct; 10(5):294-300. PMID: 15530258.
      View in: PubMed
    290. Lara PN, Gumerlock PH, Mack PC, Lau DH, Gandour-Edwards R, Edelman MJ, Albain KS, Law LY, Longmate J, Frankel P, Reddy GP, Israel V, Doroshow JH, Gandara DR. Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial. Clin Lung Cancer. 2004 Sep; 6(2):102-7. PMID: 15476595.
      View in: PubMed
    291. Le QT, McCoy J, Williamson S, Ryu J, Gaspar LE, Edelman MJ, Dakhil SR, Sides SD, Crowley JJ, Gandara DR. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study. Clin Cancer Res. 2004 Aug 15; 10(16):5418-24. PMID: 15328179.
      View in: PubMed
    292. Edelman MJ, Clark JI, Chansky K, Albain K, Bhoopalam N, Weiss GR, Giguere JK, Kelly K, Crowley J, Gandara DR. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clin Cancer Res. 2004 Aug 01; 10(15):5022-6. PMID: 15297403.
      View in: PubMed
    293. Lynch TJ, Adjei AA, Bunn PA, DuBois RN, Gandara DR, Giaccone G, Govindan R, Herbst RS, Johnson BE, Khuri FR, Perez-Soler R, Rosell R, Rowinsky EK, Sandler AB, Scagliotti GV, Schiller JH, Shapiro GI, Socinski MA, Hart CS. Novel agents in the treatment of lung cancer: conference summary statement. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4199s-4204s. PMID: 15217958.
      View in: PubMed
    294. Gandara DR, West H, Chansky K, Davies AM, Lau DH, Crowley J, Gumerlock PH, Hirsch FR, Franklin WA. Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4205s-4209s. PMID: 15217959.
      View in: PubMed
    295. Morgan RJ, Synold TW, Gandara D, Muggia F, Scudder S, Reed E, Margolin K, Raschko J, Leong L, Shibata S, Tetef M, Vasilev S, McGonigle K, Longmate J, Yen Y, Chow W, Somlo G, Carroll M, Doroshow JH. Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer. Cancer Chemother Pharmacol. 2004 Oct; 54(4):283-9. PMID: 15184995.
      View in: PubMed
    296. Kimura T, Holland WS, Kawaguchi T, Williamson SK, Chansky K, Crowley JJ, Doroshow JH, Lenz HJ, Gandara DR, Gumerlock PH. Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy. Ann N Y Acad Sci. 2004 Jun; 1022:55-60. PMID: 15251940.
      View in: PubMed
    297. Lara PN, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Twardowski P, Doroshow JH, Gandara DR. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer. 2004 May 15; 100(10):2125-31. PMID: 15139054.
      View in: PubMed
    298. Chen AY, Chou R, Shih SJ, Lau D, Gandara D. Enhancement of radiotherapy with DNA topoisomerase I-targeted drugs. Crit Rev Oncol Hematol. 2004 May; 50(2):111-9. PMID: 15157660.
      View in: PubMed
    299. Davies AM, Lara PN, Lau DH, Gandara DR. Treatment of extensive small cell lung cancer. Hematol Oncol Clin North Am. 2004 Apr; 18(2):373-85. PMID: 15094177.
      View in: PubMed
    300. Davies AM, Mack PC, Lara PN, Lau DH, Danenberg K, Gumerlock PH, Gandara DR. Predictive molecular markers: has the time come for routine use in lung cancer? J Natl Compr Canc Netw. 2004 Mar; 2(2):125-31. PMID: 19777702.
      View in: PubMed
    301. Lara PN, Davies AM, Mack PC, Mortenson MM, Bold RJ, Gumerlock PH, Gandara DR. Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy. Semin Oncol. 2004 Feb; 31(1 Suppl 1):40-6. PMID: 14981579.
      View in: PubMed
    302. Liu G, Gandara DR, Lara PN, Raghavan D, Doroshow JH, Twardowski P, Kantoff P, Oh W, Kim K, Wilding G. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res. 2004 Feb 01; 10(3):924-8. PMID: 14871968.
      View in: PubMed
    303. Lara PN, Laptalo L, Longmate J, Lau DH, Gandour-Edwards R, Gumerlock PH, Doroshow JH, Gandara DR. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. Clin Lung Cancer. 2004 Jan; 5(4):231-6. PMID: 14967075.
      View in: PubMed
    304. Edelman MJ, Chansky K, Gaspar LE, Leigh B, Weiss GR, Taylor SA, Crowley J, Livingston R, Gandara DR. Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713. J Clin Oncol. 2004 Jan 01; 22(1):127-32. PMID: 14701775.
      View in: PubMed
    305. Gandara DR. Developing targeted therapies for lung cancer. Clin Adv Hematol Oncol. 2003 Nov; 1(11):648-9, 690. PMID: 16258461.
      View in: PubMed
    306. Roberts PF, Straznicka M, Lara PN, Lau DH, Follette DM, Gandara DR, Benfield JR. Resection of multifocal non-small cell lung cancer when the bronchioloalveolar subtype is involved. J Thorac Cardiovasc Surg. 2003 Nov; 126(5):1597-602. PMID: 14666039.
      View in: PubMed
    307. Lara PN, Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P, Mack PC, Turrell C, Valk P, Rao J, Buckley P, Wun T, Gosselin R, Galvin I, Gumerlock PH, Lenz HJ, Doroshow JH, Gandara DR. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res. 2003 Oct 15; 9(13):4772-81. PMID: 14581348.
      View in: PubMed
    308. Lara PN, Frankel P, Mack PC, Gumerlock PH, Galvin I, Martel CL, Longmate J, Doroshow JH, Lenz HJ, Lau DH, Gandara DR. Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study. Clin Cancer Res. 2003 Oct 01; 9(12):4356-62. PMID: 14555506.
      View in: PubMed
    309. Mack PC, Davies AM, Lara PN, Gumerlock PH, Gandara DR. Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer. Lung Cancer. 2003 Aug; 41 Suppl 1:S89-96. PMID: 12867067.
      View in: PubMed
    310. Doroshow JH, Synold TW, Gandara D, Mani S, Remick SC, Mulkerin D, Hamilton A, Sharma S, Ramanathan RK, Lenz HJ, Graham M, Longmate J, Takimoto CH, Ivy P. Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol. 2003 Aug; 30(4 Suppl 15):14-9. PMID: 14523790.
      View in: PubMed
    311. Wild CA, Wang SE, Gandara DR, Lara PN, Meyers FJ, Tanaka M, Houston J, Lauder J, Lau DH. Population-based maximum tolerated dose of irinotecan and carboplatin. Oncology (Williston Park). 2003 Jul; 17(7 Suppl 7):11-6. PMID: 12886868.
      View in: PubMed
    312. Gandara DR, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara PN, Burris H, Gumerlock P, Kuebler JP, Bearden JD, Crowley J, Livingston R. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol. 2003 May 15; 21(10):2004-10. PMID: 12743155.
      View in: PubMed
    313. Davies AM, Lara PN, Mack PC, Gandara DR. Docetaxel in non-small cell lung cancer: a review. Expert Opin Pharmacother. 2003 Apr; 4(4):553-65. PMID: 12667118.
      View in: PubMed
    314. Mack PC, Gandara DR, Lau AH, Lara PN, Edelman MJ, Gumerlock PH. Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma. Cancer Chemother Pharmacol. 2003 Apr; 51(4):337-48. PMID: 12721762.
      View in: PubMed
    315. Edelman MJ, Gandara DR, Hausner P, Israel V, Thornton D, DeSanto J, Doyle LA. Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer. 2003 Feb; 39(2):197-9. PMID: 12581573.
      View in: PubMed
    316. Lim N, Lara PN, Lau DH, Edelman MJ, Tanaka M, al-Jazayrly G, Houston J, Lauder I, Gandara DR. Phase I trial of gemcitabine and paclitaxel in advanced solid tumors. Cancer Invest. 2003; 21(1):7-13. PMID: 12643004.
      View in: PubMed
    317. Juhasz A, Frankel P, Cheng C, Rivera H, Vishwanath R, Chiu A, Margolin K, Yen Y, Newman EM, Synold T, Wilczynski S, Lenz HJ, Gandara D, Albain KS, Longmate J, Doroshow JH. Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products. J Clin Lab Anal. 2003; 17(5):184-94. PMID: 12938148.
      View in: PubMed
    318. Davies AM, Gandara DR, Lara PN, Mack PC, Lau DH, Gumerlock PH. Antisense oligonucleotides in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 2003 Jan; 4 Suppl 2:S68-73. PMID: 14720340.
      View in: PubMed
    319. Perez EA, Gandara DR, Edelman MJ, O'Donnell R, Lauder IJ, DeGregorio M. Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies. Cancer Invest. 2003; 21(1):1-6. PMID: 12643003.
      View in: PubMed
    320. Vokes EE, Choy H, Gandara D, Mattson K. Adjuvant and neoadjuvant treatments for NSCLC. Lung Cancer. 2002 Dec; 38 Suppl 4:29-35. PMID: 12480192.
      View in: PubMed
    321. Yen Y, Chow W, Leong L, Margolin K, Morgan R, Raschko J, Shibata S, Somlo G, Twardowski P, Frankel P, Longmate J, Synold T, Newman EM, Lenz HJ, Gandara D, Doroshow JH. Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial. Cancer Chemother Pharmacol. 2002 Nov; 50(5):353-9. PMID: 12439592.
      View in: PubMed
    322. Albain KS, Crowley JJ, Turrisi AT, Gandara DR, Farrar WB, Clark JI, Beasley KR, Livingston RB. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol. 2002 Aug 15; 20(16):3454-60. PMID: 12177106.
      View in: PubMed
    323. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sánchez JM, Gumerlock PH, Tarón M, Sánchez JJ, Danenberg KD, Danenberg PV, Rosell R. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002 Jul; 8(7):2286-91. PMID: 12114432.
      View in: PubMed
    324. Hesketh PJ, Nauman CJ, Hesketh AM, LaPointe J, Fogarty K, Oo TH, Lau DH, Edelman MJ, Gandara DR. Unfavorable therapeutic index of cisplatin/gemcitabine/vinorelbine in advanced non-small-cell lung cancer. Clin Lung Cancer. 2002 Jul; 4(1):47-51. PMID: 14653876.
      View in: PubMed
    325. Davies A, Gandara DR, Lara P, Goldberg Z, Roberts P, Lau D. Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer. Semin Oncol. 2002 Jun; 29(3 Suppl 12):10-6. PMID: 12170446.
      View in: PubMed
    326. Lara PN, Meyers FJ, Gray CR, Edwards RG, Gumerlock PH, Kauderer C, Tichauer G, Twardowski P, Doroshow JH, Gandara DR. HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial. Cancer. 2002 May 15; 94(10):2584-9. PMID: 12173324.
      View in: PubMed
    327. De Castro J, Feliu J, Casado E, Ordoñez A, González Barón M. Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma. Carboplatin and gemcitabine followed by paclitaxel. Cancer. 2002 May 15; 94(10):2797-8; author reply 2798-9. PMID: 12173351.
      View in: PubMed
    328. Lara PN, Goldberg Z, Davies A, Lau DH, Gandara DR. Concurrent chemoradiation strategies in the management of unresectable stage III non-small-cell lung cancer. Clin Lung Cancer. 2002 May; 3 Suppl 2:S42-8. PMID: 14720347.
      View in: PubMed
    329. Moinpour CM, Lyons B, Grevstad PK, Lovato LC, Crowley J, Czaplicki K, Buckner ZM, Ganz PA, Kelly K, Gandara DR. Quality of life in advanced non-small-cell lung cancer: results of a Southwest Oncology Group randomized trial. Qual Life Res. 2002 Mar; 11(2):115-26. PMID: 12018735.
      View in: PubMed
    330. Ramsey SD, Moinpour CM, Lovato LC, Crowley JJ, Grevstad P, Presant CA, Rivkin SE, Kelly K, Gandara DR. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Natl Cancer Inst. 2002 Feb 20; 94(4):291-7. PMID: 11854391.
      View in: PubMed
    331. Lara PN, Lau DH, Gandara DR. Non-small-cell lung cancer progression after first-line chemotherapy. Curr Treat Options Oncol. 2002 Feb; 3(1):53-8. PMID: 12057087.
      View in: PubMed
    332. Gandara DR, Lara PN, Goldberg Z, Le QT, Mack PC, Lau DH, Gumerlock PH. Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia. Semin Oncol. 2002 Feb; 29(1 Suppl 4):102-9. PMID: 11894020.
      View in: PubMed
    333. Quock J, Dea G, Tanaka M, Gandara D, Lara P, Lau D. Premedication strategy for weekly paclitaxel. Cancer Invest. 2002; 20(5-6):666-72. PMID: 12197222.
      View in: PubMed
    334. Kuriakose P, Gandara DR, Perez EA. Phase I trial of edatrexate in advanced breast and other cancers. Cancer Invest. 2002; 20(4):473-9. PMID: 12094542.
      View in: PubMed
    335. Gandara DR, Lara PN, Lau DH, Mack P, Gumerlock PH. Molecular-clinical correlative studies in non-small cell lung cancer: application of a three-tiered approach. Lung Cancer. 2001 Dec; 34 Suppl 3:S75-80. PMID: 11740998.
      View in: PubMed
    336. Kelly K, Lovato L, Bunn PA, Livingston RB, Zangmeister J, Taylor SA, Roychowdhury D, Crowley JJ, Gandara DR. Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group. Clin Cancer Res. 2001 Aug; 7(8):2325-9. PMID: 11489808.
      View in: PubMed
    337. Thomas CR, Giroux DJ, Janaki LM, Turrisi AT, Crowley JJ, Taylor SA, McCracken JD, Shankir Giri PG, Gordon W, Livingston RB, Gandara DR. Ten-year follow-up of Southwest Oncology Group 8269: a phase II trial of concomitant cisplatin-etoposide and daily thoracic radiotherapy in limited small-cell lung cancer. Lung Cancer. 2001 Aug-Sep; 33(2-3):213-9. PMID: 11551416.
      View in: PubMed
    338. Edelman MJ, Gandara DR, Lau DH, Lara P, Lauder IJ, Tracy D. Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel. Cancer. 2001 Jul 01; 92(1):146-52. PMID: 11443620.
      View in: PubMed
    339. Kelly K, Crowley J, Bunn PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001 Jul 01; 19(13):3210-8. PMID: 11432888.
      View in: PubMed
    340. Lara PN, Gandara DR, Longmate J, Gumerlock PH, Lau DH, Edelman MJ, Gandour-Edwards R, Mack PC, Israel V, Raschko J, Frankel P, Perez EA, Lenz HJ, Doroshow JH. Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial. Cancer Chemother Pharmacol. 2001 Jul; 48(1):22-8. PMID: 11488520.
      View in: PubMed
    341. Tetef ML, Synold TW, Chow W, Leong L, Margolin K, Morgan R, Raschko J, Shibata S, Somlo G, Yen Y, Groshen S, Johnson K, Lenz HJ, Gandara D, Doroshow JH. Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies. Clin Cancer Res. 2001 Jun; 7(6):1569-76. PMID: 11410492.
      View in: PubMed
    342. Gandara DR, Lara PN, Goldberg Z, Lau DH. Integration of new chemotherapeutic agents into chemoradiotherapy for stage III non--small cell lung cancer: focus on docetaxel. Semin Oncol. 2001 Jun; 28(3 Suppl 9):26-32. PMID: 11441412.
      View in: PubMed
    343. Lippman SM, Lee JJ, Karp DD, Vokes EE, Benner SE, Goodman GE, Khuri FR, Marks R, Winn RJ, Fry W, Graziano SL, Gandara DR, Okawara G, Woodhouse CL, Williams B, Perez C, Kim HW, Lotan R, Roth JA, Hong WK. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst. 2001 Apr 18; 93(8):605-18. PMID: 11309437.
      View in: PubMed
    344. Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, Gandara DR, O'Connell M, Shepherd FA, Johnson BE. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol. 2001 Mar 15; 19(6):1734-42. PMID: 11251004.
      View in: PubMed
    345. Lara PN, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, Wun T, Welborn J, Meyers FJ, Christensen S, O'Donnell R, Richman C, Scudder SA, Tuscano J, Gandara DR, Lam KS. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001 Mar 15; 19(6):1728-33. PMID: 11251003.
      View in: PubMed
    346. Gandara DR, Edelman MJ, Lara PN, Lau DH. Gemcitabine in combination with new platinum compounds: an update. Oncology (Williston Park). 2001 Mar; 15(3 Suppl 6):13-7. PMID: 11301843.
      View in: PubMed
    347. Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Johnson D, Goldberg M, Detterbeck F, Shepherd F, Burkes R, Winton T, Deschamps C, Livingston R, Gandara D. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg. 2001 Mar; 121(3):472-83. PMID: 11241082.
      View in: PubMed
    348. Gandara DR, Lara PN, Goldberg Z, Roberts P, Lau DH. Neoadjuvant therapy for non-small cell lung cancer. Anticancer Drugs. 2001 Feb; 12 Suppl 1:S5-9. PMID: 11340902.
      View in: PubMed
    349. Lau D, Leigh B, Gandara D, Edelman M, Morgan R, Israel V, Lara P, Wilder R, Ryu J, Doroshow J. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial. J Clin Oncol. 2001 Jan 15; 19(2):442-7. PMID: 11208837.
      View in: PubMed
    350. Margolin K, Longmate J, Synold TW, Gandara DR, Weber J, Gonzalez R, Johansen MJ, Newman R, Baratta T, Doroshow JH. Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium. Invest New Drugs. 2001; 19(4):335-40. PMID: 11561695.
      View in: PubMed
    351. Macdonald JS, Jacobson JL, Modiano M, Moore DF, Gandara DR, Schroder LE, Chapman RA. A phase II trial of etoposide, leucovorin, 5-FU, and interferon alpha 2b (ELFI) + G-CSF for patients with pancreatic adenocarcinoma: a Southwest Oncology Group study (SWOG 9413). Invest New Drugs. 2000 Aug; 18(3):269-73. PMID: 10958597.
      View in: PubMed
    352. Gandara DR, Edelman M, Lara P, Roberts P, Leigh B. Evolution of combined modality therapy for stage III non-small-cell lung cancer. Oncology (Williston Park). 2000 Jul; 14(7 Suppl 5):35-41. PMID: 10981289.
      View in: PubMed
    353. Gandara DR, Lau DH, Lara PN, Edelman MJ. Gemcitabine/carboplatin combination regimens: importance of dose schedule. Oncology (Williston Park). 2000 Jul; 14(7 Suppl 4):26-30. PMID: 10960942.
      View in: PubMed
    354. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000 Jun; 18(12):2354-62. PMID: 10856094.
      View in: PubMed
    355. O'Brate A, Tarón M, Gandara D, Rosell R. Sharing new approaches to translational research in non-small cell lung cancer. Oncologist. 2000; 5(6):514-9. PMID: 11110605.
      View in: PubMed
    356. Gandara DR, Vokes E, Green M, Bonomi P, Devore R, Comis R, Carbone D, Karp D, Belani C. Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol. 2000 Jan; 18(1):131-5. PMID: 10623703.
      View in: PubMed
    357. Hesketh PJ, Roman A, Hesketh AM, Perez EA, Edelman M, Gandara DR. Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen. Support Care Cancer. 2000 Jan; 8(1):46-8. PMID: 10650897.
      View in: PubMed
    358. Gandara DR, Leigh B, Vallieres E, Albain KS. Preoperative chemotherapy in stage III non-small cell lung cancer: long-term outcome. Lung Cancer. 1999 Oct; 26(1):3-6. PMID: 10574675.
      View in: PubMed
    359. Mack PC, Gandara DR, Bowen C, Edelman MJ, Paglieroni T, Schnier JB, Gelmann EP, Gumerlock PH. RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma. Clin Cancer Res. 1999 Sep; 5(9):2596-604. PMID: 10499638.
      View in: PubMed
    360. Edelman MJ, Gandara DR, Meyers FJ, Ishii R, O'Mahony M, Uhrich M, Lauder I, Houston J, Gietzen DW. Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome. Cancer. 1999 Aug 15; 86(4):684-8. PMID: 10440697.
      View in: PubMed
    361. Murray N, Livingston RB, Shepherd FA, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin JW, Grafton C, Turrisi A, Walde D, Croft H, Osoba D, Ottaway J, Gandara D. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol. 1999 Aug; 17(8):2300-8. PMID: 10561291.
      View in: PubMed
    362. Hesketh PJ, Crowley JJ, Burris HA, Williamson SK, Balcerzak SP, Peereboom D, Goodwin JW, Gross HM, Moore DF, Livingston RB, Gandara DR. Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial. Cancer J Sci Am. 1999 Jul-Aug; 5(4):237-41. PMID: 10439170.
      View in: PubMed
    363. Gandara DR, Edelman MJ, Lau D. Emerging role of docetaxel (Taxotere) in advanced non-small cell lung cancer. Semin Oncol. 1999 Jun; 26(3 Suppl 10):3-7. PMID: 10437743.
      View in: PubMed
    364. Leigh BR, Gandara DR, Crowley JJ, Furuse K, Livingston RB, Fukushima M, Coltman CA. Summary of the proceedings of the United States--Japan lung cancer clinical trials summit: San Francisco, CA, 20-22 November, 1998. Lung Cancer. 1999 Jun; 24(3):181-91. PMID: 10460006.
      View in: PubMed
    365. ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery. Am J Health Syst Pharm. 1999 04 15; 56(8):729-64. PMID: 10326616.
      View in: PubMed
    366. Lau D, Ryu J, Gandara D, Morgan R, Doroshow J, Wilder R, Leigh B. Concurrent twice-weekly paclitaxel and thoracic irradiation for stage III non-small cell lung cancer. Semin Radiat Oncol. 1999 Apr; 9(2 Suppl 1):117-20. PMID: 10210550.
      View in: PubMed
    367. Langer CJ, Gandara DR, Calvert P, Edelman MJ, Ozols RF. Gemcitabine and carboplatin in combination: an update of phase I and phase II studies in non-small cell lung cancer. Semin Oncol. 1999 Feb; 26(1 Suppl 4):12-8. PMID: 10201516.
      View in: PubMed
    368. Grunberg SM, Crowley J, Hande KR, Giroux D, Munshi N, Lau DH, Schroder LE, Zangmeister MH, Balcerzak SP, Hynes HE, Gandara DR. Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study. Cancer Chemother Pharmacol. 1999; 44(6):461-8. PMID: 10550566.
      View in: PubMed
    369. Sondak VK, Liu PY, Flaherty LE, Fletcher WS, Periman P, Gandara DR, Taylor SA, Balcerzak SP, Meyskens FL. A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study. Cancer J Sci Am. 1999 Jan-Feb; 5(1):41-7. PMID: 10188060.
      View in: PubMed
    370. Lau DH, Crowley JJ, Gandara DR, Hazuka MB, Albain KS, Leigh B, Fletcher WS, Lanier KS, Keiser WL, Livingston RB. Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer. J Clin Oncol. 1998 Sep; 16(9):3078-81. PMID: 9738578.
      View in: PubMed
    371. Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, Albain KS, Kelly K, Taylor SA, Gandara DR, Livingston RB. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1998 Jul; 16(7):2459-65. PMID: 9667264.
      View in: PubMed
    372. Gandara DR, Roila F, Warr D, Edelman MJ, Perez EA, Gralla RJ. Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration. Support Care Cancer. 1998 May; 6(3):237-43. PMID: 9629876.
      View in: PubMed
    373. Edelman MJ, Gandara DR. Small cell lung cancer: current status of new chemotherapeutic agents. Crit Rev Oncol Hematol. 1998 Apr; 27(3):211-20. PMID: 9649933.
      View in: PubMed
    374. Edelman MJ, Gandara DR, Perez EA, Lau D, Lauder I, Turrell C, Uhrich M, Meyers F. Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy. Invest New Drugs. 1998; 16(1):69-75. PMID: 9740546.
      View in: PubMed
    375. Lara PN, Gandara DR, Wurz GT, Lau D, Uhrich M, Turrell C, Raschko J, Edelman MJ, Synold T, Doroshow J, Muggia F, Perez EA, DeGregorio M. High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically. Cancer Chemother Pharmacol. 1998; 42(6):504-8. PMID: 9788578.
      View in: PubMed
    376. Meyskens FL, Jacobson J, Nguyen B, Weiss GR, Gandara DR, MacDonald JS. Phase II trial of oral beta-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157). Invest New Drugs. 1998; 16(2):171-3. PMID: 9848581.
      View in: PubMed
    377. Lau DH, Ryu JK, Gandara DR. Chemoradiotherapy for poor-risk stage III non-small cell lung cancer. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-110-S12-112. PMID: 9331133.
      View in: PubMed
    378. Lau DH, Ryu JK, Gandara DR, Morgan R, Doroshow J, Wilder R, Leigh B. Twice-weekly paclitaxel and radiation for stage III non-small cell lung cancer. Semin Oncol. 1997 Aug; 24(4 Suppl 12):S12-106-S12-109. PMID: 9331132.
      View in: PubMed
    379. Hesketh PJ, Gandara DR, Hesketh AM, Edelman M, Webber LM, McManus M, Hainsworth JD. Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone. Cancer J Sci Am. 1997 May-Jun; 3(3):180-3. PMID: 9161784.
      View in: PubMed
    380. Lau DH, Ryu JK, Gandara DR, Rosenthal SA. Concurrent carboplatin, etoposide and thoracic radiation for poor-risk stage III non-small-cell lung carcinoma: a pilot study. Int J Radiat Oncol Biol Phys. 1997 Apr 01; 38(1):157-61. PMID: 9212018.
      View in: PubMed
    381. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro MS, Gandara D, Lindley CM. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997 Jan; 15(1):103-9. PMID: 8996130.
      View in: PubMed
    382. Gandara DR, Edelman MJ, Crowley JJ, Lau DH, Livingston RB. Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study. Cancer Chemother Pharmacol. 1997; 41(1):75-8. PMID: 9443617.
      View in: PubMed
    383. Perez EA, Coe T, Turrell C, Lau D, Campbell D, Gandara D. Phase I study of paclitaxel with oral etoposide in advanced solid tumors. Cancer J Sci Am. 1996 Sep-Oct; 2(5):286-90. PMID: 9166546.
      View in: PubMed
    384. Edelman MJ, Gandara DR, Roach M, Benfield JR. Multimodality therapy in stage III non-small cell lung cancer. Ann Thorac Surg. 1996 May; 61(5):1564-72. PMID: 8633990.
      View in: PubMed
    385. Hesketh PJ, Gandara DR, Hesketh AM, Facada A, Perez EA, Webber LM, Martin LA, Cramer MB, Hahne WF. Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide. Support Care Cancer. 1996 Mar; 4(2):141-6. PMID: 8673351.
      View in: PubMed
    386. Edelman MJ, Gandara DR. Promising new agents in the treatment of non-small cell lung cancer. Cancer Chemother Pharmacol. 1996; 37(5):385-93. PMID: 8599859.
      View in: PubMed
    387. Kelly K, Crowley JJ, Bunn PA, Hazuka MB, Beasley K, Upchurch C, Weiss GR, Hicks WJ, Gandara DR, Rivkin S. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J Clin Oncol. 1995 Dec; 13(12):2924-30. PMID: 8523056.
      View in: PubMed
    388. Kaul S, Igwemezie LN, Stewart DJ, Fields SZ, Kosty M, Levithan N, Bukowski R, Gandara D, Goss G, O'Dwyer P. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors. J Clin Oncol. 1995 Nov; 13(11):2835-41. PMID: 7595746.
      View in: PubMed
    389. Roach M, Gandara DR, Yuo HS, Swift PS, Kroll S, Shrieve DC, Wara WM, Margolis L, Phillips TL. Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol. 1995 Oct; 13(10):2606-12. PMID: 7595714.
      View in: PubMed
    390. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT, Weick JK, Lonchyna VA, Presant CA, McKenna RJ, Gandara DR. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995 Aug; 13(8):1880-92. PMID: 7636530.
      View in: PubMed
    391. Navari R, Gandara D, Hesketh P, Hall S, Mailliard J, Ritter H, Friedman C, Fitts D. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. J Clin Oncol. 1995 May; 13(5):1242-8. PMID: 7738628.
      View in: PubMed
    392. Gandara DR, Nahhas WA, Adelson MD, Lichtman SM, Podczaski ES, Yanovich S, Homesley HD, Braly P, Ritch PS, Weisberg SR. Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. J Clin Oncol. 1995 Feb; 13(2):490-6. PMID: 7844610.
      View in: PubMed
    393. Mirimanoff RO, Rubin P, Cox JD, Gandara D, Grunenwald D, Hazuka M, Jassem J, Komaki R, Mattson K, McDonald S. Concomitant and alternating radiation therapy (RT) and chemotherapy (CT) for inoperable, M0, non-small cell lung cancers (NSCLC): a consensus report. Lung Cancer. 1994 Nov; 11 Suppl 3:S5-8. PMID: 7704513.
      View in: PubMed
    394. Perez EA, Gandara DR. Etoposide/ifosfamide/cisplatin regimens in metastatic non-small cell lung cancer. Semin Oncol. 1994 Jun; 21(3 Suppl 4):2-5. PMID: 8209273.
      View in: PubMed
    395. Perez EA, Gandara DR. The clinical role of granisetron (Kytril) in the prevention of chemotherapy-induced emesis. Semin Oncol. 1994 Jun; 21(3 Suppl 5):15-21. PMID: 8042032.
      View in: PubMed
    396. Perez EA, Sowray PC, Gardner SL, Gandara DR. Phase I study of high-dose cisplatin, ifosfamide, and etoposide. Cancer Chemother Pharmacol. 1994; 34(4):331-4. PMID: 8033300.
      View in: PubMed
    397. Albain KS, Crowley JJ, Hutchins L, Gandara D, O'Bryan RM, Von Hoff DD, Griffin B, Livingston RB. Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base. Cancer. 1993 Aug 15; 72(4):1184-91. PMID: 8393365.
      View in: PubMed
    398. Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G, Neefe JR, Hutchins LF, Roach RW, Grunberg SM. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol. 1993 May; 11(5):873-8. PMID: 8387576.
      View in: PubMed
    399. Valone FH, Gandara DR, Luce JA, Wall S, Perez EA, Braham N, George M, Letvak L. Phase I trial of a 5-day infusion of L-leucovorin plus daily bolus 5-fluorouracil in patients with advanced gastrointestinal malignancies. Cancer Chemother Pharmacol. 1993; 32(3):215-20. PMID: 8500227.
      View in: PubMed
    400. Gandara DR, Harvey WH, Monaghan GG, Perez EA, Hesketh PJ. Delayed emesis following high-dose cisplatin: a double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo. Eur J Cancer. 1993; 29A Suppl 1:S35-8. PMID: 8427724.
      View in: PubMed
    401. Beck TM, Hesketh PJ, Madajewicz S, Navari RM, Pendergrass K, Lester EP, Kish JA, Murphy WK, Hainsworth JD, Gandara DR. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol. 1992 Dec; 10(12):1969-75. PMID: 1453211.
      View in: PubMed
    402. Perez EA, Gandara DR. Advances in the control of chemotherapy-induced emesis. Ann Oncol. 1992 Aug; 3 Suppl 3:47-50. PMID: 1390317.
      View in: PubMed
    403. Gandara DR, Harvey WH, Monaghan GG, Perez EA, Stokes C, Bryson JC, Finn AL, Hesketh PJ. The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. Semin Oncol. 1992 Aug; 19(4 Suppl 10):67-71. PMID: 1387253.
      View in: PubMed
    404. Carlson RW, Sikic BI, Gandara DR, Hendrickson CG, Wittlinger PS, Shields JA, Wong PP, White JE, Meakin CJ, McWhirter KM. Late consolidative radiation therapy in the treatment of limited-stage small cell lung cancer. Cancer. 1991 Sep 01; 68(5):948-58. PMID: 1655219.
      View in: PubMed
    405. Valone FH, Gandara DR, Deisseroth AB, Perez EA, Rayner A, Aronson FR, Luce J, Paradise C. Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas. J Immunother (1991). 1991 Jun; 10(3):207-13. PMID: 1651106.
      View in: PubMed
    406. Hainsworth J, Harvey W, Pendergrass K, Kasimis B, Oblon D, Monaghan G, Gandara D, Hesketh P, Khojasteh A, Harker G. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol. 1991 May; 9(5):721-8. PMID: 1826739.
      View in: PubMed
    407. Hesketh PJ, Gandara DR. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst. 1991 May 01; 83(9):613-20. PMID: 1850806.
      View in: PubMed
    408. Gandara DR, Valone FH, Perez EA, Deisseroth AB, Roach M, Ahn DK, Phillips T. Rapidly alternating radiotherapy and high dose cisplatin chemotherapy in stage IIIB non-small cell lung cancer: results of a phase I/II study. Int J Radiat Oncol Biol Phys. 1991 May; 20(5):1047-52. PMID: 1850719.
      View in: PubMed
    409. Perez EA, Hesketh PJ, Gandara DR. Serotonin antagonists in the management of cisplatin-induced emesis. Semin Oncol. 1991 Feb; 18(1 Suppl 3):73-80. PMID: 2003230.
      View in: PubMed
    410. Perez EA, Scudder SA, Meyers FA, Tanaka MS, Paradise C, Gandara DR. Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma: a phase I study. J Immunother (1991). 1991 Feb; 10(1):57-62. PMID: 2012799.
      View in: PubMed
    411. Gandara DR, Perez EA, Weibe V, De Gregorio MW. Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity. Semin Oncol. 1991 Feb; 18(1 Suppl 3):49-55. PMID: 1848372.
      View in: PubMed
    412. Gandara DR. Progress in the control of acute and delayed emesis induced by cisplatin. Eur J Cancer. 1991; 27 Suppl 1:S9-11; discussion S22. PMID: 1831633.
      View in: PubMed
    413. Khojasteh A, Sartiano G, Tapazoglou E, Lester E, Gandara D, Bernard S, Finn A. Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study. Cancer. 1990 Sep 15; 66(6):1101-5. PMID: 2144788.
      View in: PubMed
    414. Lawrence HJ, Gandara DR. Chromosomal abnormalities in non-Hodgkin's lymphoma. N Engl J Med. 1990 Feb 15; 322(7):475. PMID: 2300113.
      View in: PubMed
    415. Gandara DR, Wiebe VJ, Perez EA, Makuch RW, DeGregorio MW. Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate. Crit Rev Oncol Hematol. 1990; 10(4):353-65. PMID: 2177606.
      View in: PubMed
    416. Gandara DR, Perez EA, Wold H, Caggiano V, Malec M, Ahn DK, Meyers F, Carlson RW. High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer: a phase II study of the Northern California Oncology Group. Cancer Chemother Pharmacol. 1990; 27(3):243-7. PMID: 2176134.
      View in: PubMed
    417. Cobos E, Gandara DR, Geier LJ, Kirmani S. Post-transfusion purpura and isoimmune neonatal thrombocytopenia in the same family. Am J Hematol. 1989 Nov; 32(3):235-6. PMID: 2816919.
      View in: PubMed
    418. Gandara DR, Perez EA, Phillips WA, Lawrence HJ, DeGregorio M. Evaluation of cisplatin dose intensity: current status and future prospects. Anticancer Res. 1989 Jul-Aug; 9(4):1121-8. PMID: 2683991.
      View in: PubMed
    419. Hesketh PJ, Murphy WK, Lester EP, Gandara DR, Khojasteh A, Tapazoglou E, Sartiano GP, White DR, Werner K, Chubb JM. GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol. 1989 Jun; 7(6):700-5. PMID: 2523957.
      View in: PubMed
    420. Gandara DR, Wold H, Perez EA, Deisseroth AB, Doroshow J, Meyers F, McWhirter K, Hannigan J, De Gregorio MW. Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen. J Natl Cancer Inst. 1989 May 10; 81(10):790-4. PMID: 2541260.
      View in: PubMed
    421. Gandara DR, Perez EA, Denham A, Wiebe VJ, DeGregorio MW. Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens. Cancer Chemother Pharmacol. 1989; 24(2):135-6. PMID: 2786459.
      View in: PubMed
    422. Lawrence HJ, Walsh D, Zapotowski KA, Denham A, Goodnight SH, Gandara DR. Topical dimethylsulfoxide may prevent tissue damage from anthracycline extravasation. Cancer Chemother Pharmacol. 1989; 23(5):316-8. PMID: 2706738.
      View in: PubMed
    423. DeGregorio MW, Gandara DR, Holleran WM, Perez EA, King CC, Wold HG, Montine TJ, Borch RF. High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy: preliminary pharmacologic observations. Cancer Chemother Pharmacol. 1989; 23(5):276-8. PMID: 2539912.
      View in: PubMed
    424. Gandara DR, Perez EA, DeGregorio MW, Borch R. Cisplatin and fluorouracil with or without sodium diethyldithiocarbamate rescue. J Clin Oncol. 1988 Nov; 6(11):1785-7. PMID: 2846792.
      View in: PubMed
    425. Gandara DR, Mackenzie MR. Differential diagnosis of monoclonal gammopathy. Med Clin North Am. 1988 Sep; 72(5):1155-67. PMID: 3137401.
      View in: PubMed
    426. Perez EA, Tanaka M, Gandara DR. Conjugated estrogen for platelet dysfunction associated with liver disease. N Engl J Med. 1988 Jun 09; 318(23):1543. PMID: 2835682.
      View in: PubMed
    427. Hutchison FN, Perez EA, Gandara DR, Lawrence HJ, Kaysen GA. Renal salt wasting in patients treated with cisplatin. Ann Intern Med. 1988 Jan; 108(1):21-5. PMID: 3337511.
      View in: PubMed
    428. McLeod BF, Lawrence HJ, Smith DW, Vogt PJ, Gandara DR. Fatal bleomycin toxicity from a low cumulative dose in a patient with renal insufficiency. Cancer. 1987 Dec 01; 60(11):2617-20. PMID: 2445461.
      View in: PubMed
    429. Benz C, Gandara D, Miller B, Drakes T, Monroe S, Wilbur B, DeGregorio M. Chemoendocrine therapy with prolonged estrogen priming in advanced breast cancer: endocrine pharmacokinetics and toxicity. Cancer Treat Rep. 1987 Mar; 71(3):283-9. PMID: 3493069.
      View in: PubMed
    430. Gandara DR, George CB, Ries CA, Koretz MM, Lewis JP. Treatment of refractory chronic lymphocytic leukemia with prednimustine: a phase II study using strict response criteria. Cancer Chemother Pharmacol. 1987; 19(2):165-8. PMID: 3568275.
      View in: PubMed
    431. Valone FH, Kohler M, Fisher K, Hannigan J, Flam M, Gandara D, Hendrickson C, Richman E, Yu KP. A Northern California Oncology Group randomized trial of leucovorin plus 5-fluorouracil versus sequential methotrexate, 5-fluorouracil, and leucovorin in patients with advanced colorectal cancer who failed treatment with 5-fluorouracil or 5-fluorodeoxyuridine alone. NCI Monogr. 1987; (5):175-7. PMID: 2963230.
      View in: PubMed
    432. Gandara DR, DeGregorio MW, Wold H, Wilbur BJ, Kohler M, Lawrence HJ, Deisseroth AB, George CB. High-dose cisplatin in hypertonic saline: reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group Pilot Study in non-small-cell lung cancer. J Clin Oncol. 1986 Dec; 4(12):1787-93. PMID: 3023557.
      View in: PubMed
    433. Gandara DR, Mansour R, Wold H, George C. Dose-limiting myelosuppression associated with high-dose cisplatin (200 mg/m2) in hypertonic saline. Cancer Treat Rep. 1986 Jun; 70(6):820-1. PMID: 3731145.
      View in: PubMed
    434. Gandara DR, Wold HG, Redmond J, Kohler M, Reynolds R, Wong P, Forsythe J, Fisher K, Lewis B. Prednimustine in refractory non-Hodgkin's lymphoma: a phase II study of the Northern California Oncology Group. Semin Oncol. 1986 Mar; 13(1 Suppl 1):14-8. PMID: 3952517.
      View in: PubMed
    435. George CB, Mansour RP, Redmond J, Gandara DR. Hepatic dysfunction and jaundice following high-dose cytosine arabinoside. Cancer. 1984 Dec 01; 54(11):2360-2. PMID: 6594185.
      View in: PubMed
    436. Torti FM, Porzig KJ, Gandara DR, Volberding P, Mitchell E, Meyers FJ, Kohler M, Gribble M. Phase II trial of 4'-epi-doxorubicin in metastatic melanoma. Cancer Treat Rep. 1984 Dec; 68(12):1509-10. PMID: 6595059.
      View in: PubMed
    437. Daniels JR, Chak LY, Sikic BI, Lockbaum P, Kohler M, Carter SK, Reynolds R, Bohnen R, Gandara D, Yu J. Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs. J Clin Oncol. 1984 Nov; 2(11):1192-9. PMID: 6092554.
      View in: PubMed
    438. Chapman GS, Kumar D, Redmond J, Munderloh SH, Gandara DR. Upper abdominal computerized tomography scanning in staging non-small cell lung carcinoma. Cancer. 1984 Oct 15; 54(8):1541-3. PMID: 6478395.
      View in: PubMed
    439. Swift JF, Wold HG, Gandara DR, Redmond J, George CB. Prolymphocytic leukemia. Serial responses to therapy. Cancer. 1984 Sep 15; 54(6):978-80. PMID: 6590113.
      View in: PubMed
    440. Volk SA, Mansour RF, Gandara DR, Redmond J. Morbidity in long-term survivors of small cell carcinoma of the lung. Cancer. 1984 Jul 01; 54(1):25-7. PMID: 6326998.
      View in: PubMed
    441. Redmond J, Stites DP, Beckstead JH, George CB, Casavant CH, Gandara DR. Chronic lymphocytic leukemia with osteolytic bone lesions, hypercalcemia, and monoclonal protein. Am J Clin Pathol. 1983 May; 79(5):616-20. PMID: 6188367.
      View in: PubMed
    442. Chapman GS, Kumar D, Redmond J, Gandara DR. Upper abdominal CT scanning in staging non-oat-cell lung carcinoma. N Engl J Med. 1982 Jul 15; 307(3):189. PMID: 7088061.
      View in: PubMed
    443. Gandara DR, Ries CA, Schiff SA, George CB, Lewis JP, Koretz MM, Carter SK. A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts. Cancer Chemother Pharmacol. 1982; 9(1):10-2. PMID: 7139848.
      View in: PubMed
    444. Gandara DR, Fariss BL. Persistence of periodic paralysis following treatment of thyrotoxicosis: case report. Mil Med. 1979 May; 144(5):337-8. PMID: 113707.
      View in: PubMed
    445. Schlesinger JJ, Gandara D, Bensch KG. Myoglobinuria associated with herpes-group viral infections. Arch Intern Med. 1978 Mar; 138(3):422-4. PMID: 629637.
      View in: PubMed